|
FR2470599A1
(fr)
*
|
1979-12-07 |
1981-06-12 |
Panoz Donald |
Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
|
|
US4344929A
(en)
*
|
1980-04-25 |
1982-08-17 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
|
JPS5770816A
(en)
*
|
1980-10-17 |
1982-05-01 |
Ono Pharmaceut Co Ltd |
Multilayered film preparation of prostagladin of prolonged action
|
|
FR2525474A1
(fr)
*
|
1982-04-26 |
1983-10-28 |
Roussel Uclaf |
Nouvelle forme pharmaceutique orale de clometacine
|
|
US4478596A
(en)
*
|
1982-11-26 |
1984-10-23 |
Michelson Paul E |
Delivery system for physiologically active agents
|
|
US4613330A
(en)
*
|
1982-11-26 |
1986-09-23 |
Michelson Paul E |
Delivery system for desired agents
|
|
NZ206600A
(en)
*
|
1983-05-11 |
1987-01-23 |
Alza Corp |
Osmotic drug delivery device
|
|
JPH075457B2
(ja)
*
|
1983-08-16 |
1995-01-25 |
ザ ウエルカム フアウンデ−シヨン リミテツド |
調節された方法による有効成分の放出を可能にする医薬組成物
|
|
US4670578A
(en)
*
|
1983-08-29 |
1987-06-02 |
Merck & Co., Inc. |
Process for crystalline salts of L or (S)-3-(3,4-dihydroxyphenyl)-2-methylalanine esters
|
|
EP0137364A3
(en)
*
|
1983-09-23 |
1986-10-22 |
Merck & Co. Inc. |
Suppository form of an osmotic therapeutic system
|
|
US4627850A
(en)
*
|
1983-11-02 |
1986-12-09 |
Alza Corporation |
Osmotic capsule
|
|
GB2150434B
(en)
*
|
1983-12-01 |
1987-11-04 |
Alza Corp |
Constant rate release systems
|
|
GB2150830B
(en)
*
|
1983-12-05 |
1987-08-19 |
Alza Corp |
Drug dispenser
|
|
US4725427A
(en)
*
|
1984-03-13 |
1988-02-16 |
Albion International, Inc. |
Effervescent vitamin-mineral granule preparation
|
|
US4595583A
(en)
*
|
1984-03-19 |
1986-06-17 |
Alza Corporation |
Delivery system controlled administration of beneficial agent to ruminants
|
|
US4717566A
(en)
*
|
1984-03-19 |
1988-01-05 |
Alza Corporation |
Dosage system and method of using same
|
|
DE3586445T2
(de)
|
1984-06-26 |
1993-01-14 |
Merck & Co Inc |
Kondensierte benzo-laktam-verbindungen und deren pharmazeutische zusammensetzungen.
|
|
US4693895A
(en)
*
|
1984-10-26 |
1987-09-15 |
Alza Corporation |
Colon delivery system
|
|
US4627971A
(en)
*
|
1985-04-22 |
1986-12-09 |
Alza Corporation |
Osmotic device with self-sealing passageway
|
|
US4624847A
(en)
*
|
1985-04-22 |
1986-11-25 |
Alza Corporation |
Drug delivery device for programmed delivery of beneficial drug
|
|
US4675174A
(en)
*
|
1985-08-16 |
1987-06-23 |
Alza Corporation |
Veterinary dispenser delivering beneficial agent by gas power generated in situ
|
|
US4723957A
(en)
*
|
1986-02-07 |
1988-02-09 |
Alza Corp. |
System for delivering drug with enhanced bioacceptability
|
|
US4971790A
(en)
*
|
1986-02-07 |
1990-11-20 |
Alza Corporation |
Dosage form for lessening irritation of mocusa
|
|
US4662880A
(en)
*
|
1986-03-14 |
1987-05-05 |
Alza Corporation |
Pseudoephedrine, brompheniramine therapy
|
|
US4753802A
(en)
*
|
1986-03-19 |
1988-06-28 |
Alza Corporation |
Verapamil dosage form
|
|
US4847093A
(en)
*
|
1986-06-19 |
1989-07-11 |
Alza Corporation |
Dosage form with means for governing rate of gas formation
|
|
US5143908A
(en)
*
|
1986-11-05 |
1992-09-01 |
Merck & Co., Inc. |
Antibacterial agents and potentiators of carbapenem antibiotics
|
|
US5099063A
(en)
*
|
1986-11-05 |
1992-03-24 |
Merck & Co., Inc. |
Certain phosphinic acid derivatives having antibacterial activity
|
|
US4715994A
(en)
*
|
1986-11-05 |
1987-12-29 |
Merck & Co., Inc. |
Novel antibacterial agents and potentiators of carbapenem antibiotics
|
|
US5110597A
(en)
*
|
1987-06-25 |
1992-05-05 |
Alza Corporation |
Multi-unit delivery system
|
|
US5023088A
(en)
*
|
1987-06-25 |
1991-06-11 |
Alza Corporation |
Multi-unit delivery system
|
|
US4874388A
(en)
*
|
1987-06-25 |
1989-10-17 |
Alza Corporation |
Multi-layer delivery system
|
|
US5938654A
(en)
*
|
1987-06-25 |
1999-08-17 |
Alza Corporation |
Osmotic device for delayed delivery of agent
|
|
US5499979A
(en)
*
|
1987-06-25 |
1996-03-19 |
Alza Corporation |
Delivery system comprising kinetic forces
|
|
US4957494A
(en)
*
|
1987-06-25 |
1990-09-18 |
Alza Corporation |
Multi-layer delivery system
|
|
JPS6413097A
(en)
*
|
1987-07-06 |
1989-01-17 |
Mitsubishi Chem Ind |
Phosphonic acid derivative
|
|
US5041644A
(en)
*
|
1987-07-06 |
1991-08-20 |
Merck & Co., Inc. |
Peptide derivatives of β-chloro-L(Z)-dehydro-glutamic acid
|
|
EP0318066B1
(en)
|
1987-09-22 |
1992-07-29 |
Merck & Co. Inc. |
Aryl-substituted thiophene 3-ols, derivatives and analogs, as lipoxygenase inhibitors
|
|
US5030732A
(en)
*
|
1988-03-03 |
1991-07-09 |
Merck & Co., Inc. |
Aminoethylphosphinic acid derivatives
|
|
CH675537A5
(OSRAM)
*
|
1988-03-25 |
1990-10-15 |
Ciba Geigy Ag |
|
|
US5211957A
(en)
*
|
1988-03-25 |
1993-05-18 |
Ciba-Geigy Corporation |
Solid rapidly disintegrating dosage form
|
|
US5147867A
(en)
*
|
1988-10-28 |
1992-09-15 |
Merck & Co., Inc. |
Phosphorus containing enzyme inhibitors
|
|
US5145990A
(en)
*
|
1988-10-28 |
1992-09-08 |
Merck & Co., Inc. |
Phosphorous containing dhp enzyme inhibitors
|
|
US4962097A
(en)
*
|
1988-10-28 |
1990-10-09 |
Merck & Co., Inc. |
Method of treating bacterial infection with phosphorus containing DHP enzyme inhibitors
|
|
US4942039A
(en)
*
|
1989-05-09 |
1990-07-17 |
Miles Inc. |
Effervescent analgesic antacid composition having reduced sodium content
|
|
US5223264A
(en)
*
|
1989-10-02 |
1993-06-29 |
Cima Labs, Inc. |
Pediatric effervescent dosage form
|
|
US5089530A
(en)
|
1990-08-03 |
1992-02-18 |
Merck & Co., Inc. |
Novel fermentation product with antiparasitic activity
|
|
US5443459A
(en)
*
|
1991-01-30 |
1995-08-22 |
Alza Corporation |
Osmotic device for delayed delivery of agent
|
|
SG84487A1
(en)
|
1991-04-17 |
2001-11-20 |
Merck & Co Inc |
Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist
|
|
US5198229A
(en)
*
|
1991-06-05 |
1993-03-30 |
Alza Corporation |
Self-retaining gastrointestinal delivery device
|
|
US5223265A
(en)
*
|
1992-01-10 |
1993-06-29 |
Alza Corporation |
Osmotic device with delayed activation of drug delivery
|
|
US5639782A
(en)
*
|
1992-03-04 |
1997-06-17 |
Center For Innovative Technology |
Neolignan derivatives as platelet activating factor receptor antagonists and 5-lipoxygenase inhibitors
|
|
US5434151A
(en)
*
|
1992-08-24 |
1995-07-18 |
Cytomed, Inc. |
Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
|
|
US5463083A
(en)
*
|
1992-07-13 |
1995-10-31 |
Cytomed, Inc. |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
|
ES2152952T3
(es)
|
1992-07-13 |
2001-02-16 |
Millennium Pharm Inc |
2,5-diaril tetrahidro-tiofenos, -furanos y analogos para el tratamiento de problemas inflamatorios e inmunes.
|
|
US5498255A
(en)
*
|
1993-08-17 |
1996-03-12 |
Alza Corporation |
Osmotic device for protracted pulsatile delivery of agent
|
|
US5403952A
(en)
*
|
1993-10-08 |
1995-04-04 |
Merck & Co., Inc. |
Substituted cyclic derivatives as novel antidegenerative agents
|
|
US5792776A
(en)
*
|
1994-06-27 |
1998-08-11 |
Cytomed, Inc., |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
|
US5750565A
(en)
|
1995-05-25 |
1998-05-12 |
Cytomed, Inc. |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
|
US5703093A
(en)
*
|
1995-05-31 |
1997-12-30 |
Cytomed, Inc. |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
|
US6348571B1
(en)
|
1994-09-12 |
2002-02-19 |
Northwestern University |
Corticotropin release inhibiting factor and methods of using same
|
|
US5767113A
(en)
*
|
1995-05-10 |
1998-06-16 |
The Salk Institute For Biological Studies |
Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
|
|
US7048906B2
(en)
*
|
1995-05-17 |
2006-05-23 |
Cedars-Sinai Medical Center |
Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
|
|
CA2220451A1
(en)
*
|
1995-05-17 |
1996-11-21 |
Cedars-Sinai Medical Center |
Methods and compositions for improving digestion and absorption in the small intestine
|
|
US6558708B1
(en)
|
1995-05-17 |
2003-05-06 |
Cedars-Sinai Medical Center |
Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
|
|
US6861053B1
(en)
*
|
1999-08-11 |
2005-03-01 |
Cedars-Sinai Medical Center |
Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
|
|
US5817335A
(en)
*
|
1995-05-26 |
1998-10-06 |
Alza Corporation |
Osmotic device with high drug loading and delayed activation of drug delivery
|
|
US5741815A
(en)
*
|
1995-06-02 |
1998-04-21 |
Lai; Ching-San |
Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
|
|
US5756540A
(en)
*
|
1995-06-02 |
1998-05-26 |
Mcw Research Foundation, Inc. |
Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
|
|
US5800422A
(en)
*
|
1995-06-02 |
1998-09-01 |
Alza Corporation |
Osmotic device with delayed activation of drug delivery and complete drug release
|
|
US6372713B1
(en)
|
1995-09-08 |
2002-04-16 |
The Board Of Trustees Of Northwestern University |
Anti-depressant effects of corticotropin release inhibiting factor
|
|
US5747532A
(en)
*
|
1995-11-21 |
1998-05-05 |
Medinox, Inc. |
Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
|
|
US6723531B2
(en)
*
|
1996-04-05 |
2004-04-20 |
The Salk Institute For Biological Studies |
Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
|
|
US5902605A
(en)
*
|
1996-04-18 |
1999-05-11 |
Alza Corporation |
Drug delivery device with minimal residual drug retention
|
|
US5785688A
(en)
*
|
1996-05-07 |
1998-07-28 |
Ceramatec, Inc. |
Fluid delivery apparatus and method
|
|
US5939460A
(en)
*
|
1996-07-08 |
1999-08-17 |
Idun Pharmaceuticals, Inc. |
Method of inhibiting NADPH oxidase
|
|
US5677318A
(en)
*
|
1996-07-11 |
1997-10-14 |
Merck Frosst Canada, Inc. |
Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
|
|
US5922761A
(en)
*
|
1996-09-06 |
1999-07-13 |
Medinox, Inc. |
Methods for in vivo reduction of iron levels and compositions useful therefor
|
|
JP2002511837A
(ja)
|
1996-09-10 |
2002-04-16 |
メデイノックス,インコーポレイテッド |
ポリジチオカルバメート含有マクロ分子と、治療及び診断用途へのその使用
|
|
US5858402A
(en)
*
|
1997-02-11 |
1999-01-12 |
Medinox, Inc. |
Methods for in vivo reduction of cyanide levels and compositions useful therefor
|
|
US5916910A
(en)
|
1997-06-04 |
1999-06-29 |
Medinox, Inc. |
Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
|
|
US5985592A
(en)
*
|
1997-06-05 |
1999-11-16 |
Dalhousie University |
Uses for pentoxifylline or functional derivatives/metabolites thereof
|
|
US6294350B1
(en)
|
1997-06-05 |
2001-09-25 |
Dalhousie University |
Methods for treating fibroproliferative diseases
|
|
US5840721A
(en)
|
1997-07-09 |
1998-11-24 |
Ontogen Corporation |
Imidazole derivatives as MDR modulators
|
|
US7105496B2
(en)
*
|
1998-07-23 |
2006-09-12 |
Northwestern University |
Methods and compositions for inhibiting angiogenesis
|
|
US6797691B1
(en)
*
|
1997-07-23 |
2004-09-28 |
Northwestern University |
Methods and compositions for inhibiting angiogenesis
|
|
US20030220234A1
(en)
*
|
1998-11-02 |
2003-11-27 |
Selvaraj Naicker |
Deuterated cyclosporine analogs and their use as immunodulating agents
|
|
AU9797998A
(en)
|
1997-10-10 |
1999-05-03 |
Trustees Of The University Of Pennsylvania, The |
Compositions and methods for inhibiting arginase activity
|
|
CA2306096A1
(en)
|
1997-10-15 |
1999-04-22 |
Thomas Jefferson University |
Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
|
|
US6750201B1
(en)
*
|
1997-10-17 |
2004-06-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
|
|
US6984773B1
(en)
|
1998-01-09 |
2006-01-10 |
The Salk Institute For Biological Studies |
Transgenic mice expressing a human SXR receptor polypeptide
|
|
US6756491B2
(en)
|
1998-01-09 |
2004-06-29 |
The Salk Institute For Biological Studies |
Steroid-activated nuclear receptors and uses therefor
|
|
WO1999047549A1
(en)
*
|
1998-03-16 |
1999-09-23 |
Ontogen Corporation |
PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
|
|
US6287605B1
(en)
*
|
1998-04-17 |
2001-09-11 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treatment and prevention of HIV-1 infection
|
|
WO1999058640A2
(en)
|
1998-05-11 |
1999-11-18 |
Philadelphia Health And Education Corporation |
Mct-1, a human oncogene
|
|
US6333318B1
(en)
|
1998-05-14 |
2001-12-25 |
The Salk Institute For Biological Studies |
Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
|
|
US20030220258A1
(en)
*
|
2001-12-21 |
2003-11-27 |
Robbert Benner |
Treatment of ischemic events
|
|
US20050203187A1
(en)
*
|
1998-06-01 |
2005-09-15 |
Verbiscar Anthony J. |
Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof
|
|
US6093743A
(en)
|
1998-06-23 |
2000-07-25 |
Medinox Inc. |
Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
|
|
US6265420B1
(en)
|
1998-06-23 |
2001-07-24 |
Medinox, Inc. |
Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
|
|
US6596770B2
(en)
|
2000-05-05 |
2003-07-22 |
Medinox, Inc. |
Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
|
|
US20030064917A1
(en)
*
|
1998-07-23 |
2003-04-03 |
Crawford Susan E. |
Methods and compositions for inhibiting angiogenesis
|
|
US6565854B2
(en)
|
1998-08-13 |
2003-05-20 |
Philadelphia Health And Education Corporation |
Antimicrobial histone H1 compositions, kits, and methods of use thereof
|
|
WO2000009118A1
(en)
|
1998-08-13 |
2000-02-24 |
The Wistar Institute |
Methods for reducing atherosclerotic plaques
|
|
US6646113B1
(en)
*
|
1998-09-17 |
2003-11-11 |
The Trustees Of The University Of Pennsylvania |
Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
|
|
US20020138856A1
(en)
*
|
1998-10-23 |
2002-09-26 |
Northwestern University |
Compositions and methods useful for treatment of depressive disorder based on an animal model
|
|
DE60036915T2
(de)
|
1999-01-13 |
2008-08-07 |
Alchemia Oncology Pty Ltd., Hawthorn |
Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
|
|
US6395029B1
(en)
|
1999-01-19 |
2002-05-28 |
The Children's Hospital Of Philadelphia |
Sustained delivery of polyionic bioactive agents
|
|
US7282489B2
(en)
*
|
2000-01-19 |
2007-10-16 |
The Children's Hospital Of Philadelphia |
Compositions and methods for performing reverse gene therapy
|
|
WO2000041731A1
(en)
|
1999-01-19 |
2000-07-20 |
The Children's Hospital Of Philadelphia |
Reverse gene therapy
|
|
WO2000050402A1
(en)
|
1999-02-25 |
2000-08-31 |
Merck Frosst Canada & Co. |
Pde iv inhibiting compounds, compositions and methods of treatment
|
|
US7141417B1
(en)
|
1999-02-25 |
2006-11-28 |
Thomas Jefferson University |
Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene
|
|
US6221855B1
(en)
|
1999-03-11 |
2001-04-24 |
Wake Forest University |
Regulation of nucleic acid expression by heparan sulfate and biological equivalents thereof
|
|
US6428968B1
(en)
|
1999-03-15 |
2002-08-06 |
The Trustees Of The University Of Pennsylvania |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
|
US6025502A
(en)
*
|
1999-03-19 |
2000-02-15 |
The Trustees Of The University Of Pennsylvania |
Enantopselective synthesis of methyl phenidate
|
|
US6251927B1
(en)
|
1999-04-20 |
2001-06-26 |
Medinox, Inc. |
Methods for treatment of sickle cell anemia
|
|
AU4803800A
(en)
|
1999-04-27 |
2000-11-10 |
Trustees Of The University Of Pennsylvania, The |
Compositions, methods, and kits relating to LTiGTresistinLT/iGT
|
|
US6420545B1
(en)
|
1999-05-24 |
2002-07-16 |
The Trustees Of The University Of Pennsylvania |
CD4-independent HIV envelope proteins as vaccines and therapeutics
|
|
US7033780B1
(en)
*
|
1999-06-14 |
2006-04-25 |
Millennium Pharmaceuticals, Inc. |
Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
|
|
US7160694B2
(en)
|
1999-06-14 |
2007-01-09 |
Millennium Pharmaceuticals, Inc. |
Nucleic acids encoding TANGO405 and functional fragments and uses thereof
|
|
US6964854B1
(en)
*
|
1999-07-13 |
2005-11-15 |
Science & Technology Corporation |
Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis
|
|
US20020147197A1
(en)
*
|
1999-10-08 |
2002-10-10 |
Newman Michael J. |
Methods and compositions for enhancing pharmaceutical treatments
|
|
DE60041880D1
(de)
|
1999-10-08 |
2009-05-07 |
Taiji Biomedical Inc |
Verfahren zur verbesserung der chemotherapie
|
|
JP4754143B2
(ja)
|
1999-10-12 |
2011-08-24 |
ケモセントリックス, インコーポレイテッド |
ケモカインレセプター
|
|
US6274627B1
(en)
|
1999-10-12 |
2001-08-14 |
Medinox, Inc. |
Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor
|
|
US7057015B1
(en)
|
1999-10-20 |
2006-06-06 |
The Salk Institute For Biological Studies |
Hormone receptor functional dimers and methods of their use
|
|
JP3417370B2
(ja)
|
1999-12-09 |
2003-06-16 |
株式会社村田製作所 |
非可逆回路素子及び通信機装置
|
|
US6559128B1
(en)
*
|
2000-01-21 |
2003-05-06 |
Northwestern University |
Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
|
|
US20030212021A1
(en)
*
|
2001-01-25 |
2003-11-13 |
Frost Gregory I. |
Myeloid colony stimulating factor and uses thereof
|
|
US6464688B1
(en)
|
2000-02-15 |
2002-10-15 |
Microsolutions, Inc. |
Osmotic pump delivery system with flexible drug compartment
|
|
JP2001320205A
(ja)
|
2000-03-02 |
2001-11-16 |
Murata Mfg Co Ltd |
非可逆回路素子および通信装置
|
|
US7358330B2
(en)
*
|
2001-03-29 |
2008-04-15 |
Biotempt B.V. |
Immunoregulatory compositions
|
|
US6509315B1
(en)
|
2000-04-07 |
2003-01-21 |
The Trustees Of The University Of Pennsylvania |
Didemnin analogs and fragments and methods of making and using them
|
|
ATE339963T1
(de)
*
|
2000-04-07 |
2006-10-15 |
Univ Pennsylvania |
Tamandarin und didemnin analoga und methoden zu deren herstellung und verwendung
|
|
WO2001087870A1
(en)
|
2000-05-15 |
2001-11-22 |
Darwin Discovery Limited |
Hydroxamic acid derivatives
|
|
US6908741B1
(en)
*
|
2000-05-30 |
2005-06-21 |
Transtech Pharma, Inc. |
Methods to identify compounds that modulate RAGE
|
|
US7087632B2
(en)
*
|
2001-03-05 |
2006-08-08 |
Transtech Pharma, Inc. |
Benzimidazole derivatives as therapeutic agents
|
|
US6613801B2
(en)
*
|
2000-05-30 |
2003-09-02 |
Transtech Pharma, Inc. |
Method for the synthesis of compounds of formula I and their uses thereof
|
|
AU2001275043A1
(en)
|
2000-05-31 |
2001-12-11 |
Drugtech Corporation |
Mineral supplement
|
|
AU2001269803A1
(en)
*
|
2000-06-20 |
2002-01-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for modulating muscle cell and tissue contractility
|
|
US6429223B1
(en)
|
2000-06-23 |
2002-08-06 |
Medinox, Inc. |
Modified forms of pharmacologically active agents and uses therefor
|
|
AUPQ879500A0
(en)
*
|
2000-07-14 |
2000-08-10 |
Meditech Research Limited |
Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
|
|
US9066919B2
(en)
*
|
2000-07-14 |
2015-06-30 |
Alchemia Oncology Pty Limited |
Hyaluronan as a chemo-sensitizer in the treatment of cancer
|
|
ATE461213T1
(de)
|
2000-07-19 |
2010-04-15 |
Advanced Res & Tech Inst |
Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung
|
|
AU2001290629A1
(en)
*
|
2000-09-07 |
2002-03-22 |
Boehringer Ingelheim International G.M.B.H |
Heat shock response and virus replication
|
|
CA2460042C
(en)
*
|
2000-09-26 |
2012-05-08 |
Sidney Kimmel Cancer Center |
Inhibition of antigen presentation with poorly catabolized polymers
|
|
US20040102367A1
(en)
*
|
2001-02-23 |
2004-05-27 |
Gage Fred H |
Gene expression system based on chimeric receptors
|
|
US20030166063A1
(en)
*
|
2001-03-05 |
2003-09-04 |
Harris Robert B. |
High level insect expression of rage proteins
|
|
CN1494425B
(zh)
*
|
2001-03-05 |
2011-12-07 |
特兰斯泰克制药公司 |
用作治疗剂的羧酰胺衍生物
|
|
US7294472B2
(en)
*
|
2001-03-14 |
2007-11-13 |
Caden Biosciences |
Method for identifying modulators of G protein coupled receptor signaling
|
|
US7208279B2
(en)
*
|
2001-03-14 |
2007-04-24 |
Caden Biosciences, Inc. |
Method for identifying inhibitors of G protein coupled receptor signaling
|
|
ITMI20010733A1
(it)
|
2001-04-05 |
2002-10-05 |
Recordati Chem Pharm |
Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
|
|
US6727287B2
(en)
|
2001-04-16 |
2004-04-27 |
Pts International, Inc. |
Toluene sulfonamide-containing anti-tumor composition and method of use thereof
|
|
US6632217B2
(en)
|
2001-04-19 |
2003-10-14 |
Microsolutions, Inc. |
Implantable osmotic pump
|
|
CN1157388C
(zh)
*
|
2001-05-29 |
2004-07-14 |
北京大学 |
哌嗪基二硫代甲酸酯类化合物,它们的制备方法和在抗肿瘤药物中的应用
|
|
RU2259825C9
(ru)
|
2001-06-18 |
2006-04-10 |
БиоДием Лимитед |
Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности
|
|
UA74912C2
(en)
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
|
US6884619B2
(en)
|
2001-07-17 |
2005-04-26 |
Yale University |
Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
|
|
AU2002322515A1
(en)
*
|
2001-07-17 |
2003-03-03 |
Keith Choate |
Compositions, methods, and kits related to treating and diagnosing hypertension
|
|
GB0119396D0
(en)
*
|
2001-08-09 |
2001-10-03 |
Celltech R&D Ltd |
Hydroxamic acid derivatives
|
|
WO2003015757A1
(en)
*
|
2001-08-16 |
2003-02-27 |
The Trustees Of The University Of Pennsylvania |
Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
|
|
US9056048B2
(en)
*
|
2001-08-16 |
2015-06-16 |
The Trustees Of The University Of Pennsylvania |
Synthesis and use of cationic steroids for anti-inflammatory drug therapy
|
|
WO2003018062A1
(en)
*
|
2001-08-27 |
2003-03-06 |
Meditech Research Limited |
Improved therapeutic protocols
|
|
US20030069071A1
(en)
*
|
2001-09-28 |
2003-04-10 |
Tim Britt |
Entertainment monitoring system and method
|
|
RU2321593C9
(ru)
|
2001-10-19 |
2008-06-20 |
Изотехника Инк. |
Синтез аналогов циклоспорина
|
|
US6555563B1
(en)
|
2001-11-16 |
2003-04-29 |
Medinox, Inc. |
Heteroaryl substituted amidinyl and imidazolyl compounds and methods employing same for the treatment of inflammation
|
|
US7871619B2
(en)
*
|
2001-11-30 |
2011-01-18 |
Chemocentryx, Inc. |
Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
|
|
US7253007B2
(en)
*
|
2001-11-30 |
2007-08-07 |
Chemocentryx, Inc. |
Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
|
|
US7442512B2
(en)
*
|
2001-11-30 |
2008-10-28 |
Chemocentryx, Inc. |
Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
|
|
US7413866B2
(en)
*
|
2001-11-30 |
2008-08-19 |
Chemocentryx, Inc. |
Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
|
|
PE20030701A1
(es)
*
|
2001-12-20 |
2003-08-21 |
Schering Corp |
Compuestos para el tratamiento de trastornos inflamatorios
|
|
HUP0402309A3
(en)
|
2001-12-21 |
2008-09-29 |
Novo Nordisk As |
Amide derivatives as glucokinase activators and pharmaceutical compositions containing them
|
|
AR038136A1
(es)
|
2002-01-24 |
2004-12-29 |
Merck Frosst Canada Inc |
Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
|
|
TWI329105B
(en)
*
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
US20030161882A1
(en)
*
|
2002-02-01 |
2003-08-28 |
Waterman Kenneth C. |
Osmotic delivery system
|
|
TW200302748A
(en)
*
|
2002-02-01 |
2003-08-16 |
Pfizer Prod Inc |
Osmotic delivery system
|
|
US7378111B2
(en)
*
|
2002-02-20 |
2008-05-27 |
The Trustees Of The University Of Pennsylvania |
Regulation of GSK-3α activity for the treatment or prevention of Alzheimer's disease
|
|
JP4481011B2
(ja)
*
|
2002-03-05 |
2010-06-16 |
トランス テック ファーマ,インコーポレイテッド |
リガンドのrageとの相互作用を阻害する単環式および二環式アゾール誘導体
|
|
JP4570878B2
(ja)
|
2002-04-11 |
2010-10-27 |
メルク・シャープ・エンド・ドーム・コーポレイション |
選択的糖質コルチコイド受容体モジュレーターとしての1H−ベンゾ[f]インダゾール−5−イル誘導体
|
|
US7622117B2
(en)
*
|
2002-04-17 |
2009-11-24 |
Dynamis Therapeutics, Inc. |
3-deoxyglucosone and skin
|
|
EP1503754B1
(en)
*
|
2002-04-19 |
2005-11-23 |
Yissum Research Development Company, of The Hebrew University of Jerusalem |
Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
|
|
JP2005531544A
(ja)
*
|
2002-05-06 |
2005-10-20 |
ワシントン・ユニバーシティ |
Egfr経路の抑制による緑内障およびnos−2発現により媒介される他の状態の治療方法
|
|
AUPS234402A0
(en)
*
|
2002-05-15 |
2002-06-13 |
Auckland Uniservices Limited |
Anti-tumour polycyclic carboxamides
|
|
US20080051428A1
(en)
*
|
2002-05-15 |
2008-02-28 |
Davis Paul J |
Pyrroloquinoline quinone drugs and methods of use thereof
|
|
WO2003099773A1
(en)
|
2002-05-24 |
2003-12-04 |
Millennium Pharmaceuticals, Inc. |
Ccr9 inhibitors and methods of use thereof
|
|
AU2003236500B9
(en)
|
2002-06-12 |
2009-07-02 |
Chemocentryx, Inc. |
1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders
|
|
US20050256130A1
(en)
*
|
2002-06-12 |
2005-11-17 |
Chemocentryx, Inc. |
Substituted piperazines
|
|
US7842693B2
(en)
*
|
2002-06-12 |
2010-11-30 |
Chemocentryx, Inc. |
Substituted piperazines
|
|
US7589199B2
(en)
*
|
2002-06-12 |
2009-09-15 |
Chemocentryx, Inc. |
Substituted piperazines
|
|
US6727241B2
(en)
|
2002-06-12 |
2004-04-27 |
Chemocentryx |
Anti-inflammatory compositions and methods of use
|
|
US6620813B1
(en)
|
2002-06-21 |
2003-09-16 |
Medinox, Inc. |
Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
|
|
US20040077691A1
(en)
*
|
2002-06-21 |
2004-04-22 |
Medinox, Inc. |
Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
|
|
BR0312023A
(pt)
|
2002-06-27 |
2005-03-22 |
Novo Nordisk As |
Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
|
|
EP1558585B1
(en)
|
2002-10-04 |
2013-09-25 |
Prana Biotechnology Limited |
Neurologically-active compounds
|
|
WO2004037206A2
(en)
*
|
2002-10-23 |
2004-05-06 |
University Of Hawaii |
Methods for diagnosing and treating pre-term labor
|
|
WO2004037843A2
(en)
*
|
2002-10-25 |
2004-05-06 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
|
|
EP1558250A4
(en)
|
2002-10-30 |
2006-11-02 |
Merck & Co Inc |
GAMMA AMINOAMIDE MODULATORS OF THE CHEMOKIN RECEPTOR ACTIVITY
|
|
JP2006514101A
(ja)
|
2002-11-08 |
2006-04-27 |
ノボ・ノルデイスク・エー/エス |
肥満症の治療のための安全な化学的脱共役剤
|
|
US20050143449A1
(en)
*
|
2002-11-15 |
2005-06-30 |
The Salk Institute For Biological Studies |
Non-steroidal farnesoid X receptor modulators and methods for the use thereof
|
|
US7420055B2
(en)
*
|
2002-11-18 |
2008-09-02 |
Chemocentryx, Inc. |
Aryl sulfonamides
|
|
US7741519B2
(en)
*
|
2007-04-23 |
2010-06-22 |
Chemocentryx, Inc. |
Bis-aryl sulfonamides
|
|
DE60314175T2
(de)
*
|
2002-11-18 |
2008-01-24 |
Chemocentryx Inc., Mountain View |
Arylsulfonamide
|
|
US20070021466A1
(en)
*
|
2002-11-18 |
2007-01-25 |
Solomon Ungashe |
CCR2 inhibitors and methods of use thereof
|
|
US7227035B2
(en)
*
|
2002-11-18 |
2007-06-05 |
Chemocentryx |
Bis-aryl sulfonamides
|
|
KR100772297B1
(ko)
*
|
2002-11-22 |
2007-11-02 |
니뽄 다바코 산교 가부시키가이샤 |
융합 비시클릭 질소-함유 헤테로사이클
|
|
US20060166894A1
(en)
*
|
2002-11-29 |
2006-07-27 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Ace-inhibitors having antioxidant and no-donor activity
|
|
MXPA05006653A
(es)
|
2002-12-20 |
2005-09-30 |
Arakis Ltd |
Benzoxazocinas novedosas y sus usos terapeuticos.
|
|
MXPA05006507A
(es)
*
|
2002-12-20 |
2006-02-17 |
Chemocentryx |
Inhibidores de ccxckr2 expresado en tumor humano.
|
|
WO2004062597A2
(en)
*
|
2003-01-09 |
2004-07-29 |
The Trustees Of The University Of Pennsylvania |
Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
|
|
AU2003900927A0
(en)
*
|
2003-02-28 |
2003-03-13 |
Biodiem Ltd |
Growth promotion method
|
|
CA2519234A1
(en)
*
|
2003-03-21 |
2004-10-07 |
Madeleine M. Joullie |
Tamandarin analogs and fragments thereof and methods of making and using
|
|
EP1618090A1
(en)
|
2003-04-11 |
2006-01-25 |
Novo Nordisk A/S |
11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
|
|
JO2355B1
(en)
|
2003-04-15 |
2006-12-12 |
ميرك شارب اند دوم كوربوريشن |
Hereditary calcitonin polypeptide receptor antagonists
|
|
US8158149B2
(en)
*
|
2004-05-12 |
2012-04-17 |
Chelsea Therapeutics, Inc. |
Threo-DOPS controlled release formulation
|
|
US20060105036A1
(en)
|
2003-05-12 |
2006-05-18 |
Stephen Peroutka |
Threo-dops controlled release formulation
|
|
AR041089A1
(es)
|
2003-05-15 |
2005-05-04 |
Merck & Co Inc |
Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
|
|
WO2005000295A1
(en)
*
|
2003-05-20 |
2005-01-06 |
Transtech Pharma, Inc. |
Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
|
|
KR20120062863A
(ko)
*
|
2003-07-30 |
2012-06-14 |
리겔 파마슈티칼스, 인크. |
자가면역 질환의 치료 또는 예방에 사용하기 위한 2,4-피리미딘디아민 화합물
|
|
JP2007501801A
(ja)
*
|
2003-08-07 |
2007-02-01 |
日本たばこ産業株式会社 |
ピロロ[1,2−b]ピリダジン誘導体
|
|
EP2087905A2
(en)
|
2003-08-08 |
2009-08-12 |
Novo Nordisk A/S |
Interleukin-20 for treating and diagnosing conditions associated with neovascularisation
|
|
US8071535B2
(en)
*
|
2003-09-12 |
2011-12-06 |
The Regents Of The University Of California |
Guanidinium derivatives for improved cellular transport
|
|
WO2005033297A1
(en)
*
|
2003-09-19 |
2005-04-14 |
The Rockefeller University |
Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells
|
|
WO2005030797A2
(en)
|
2003-09-30 |
2005-04-07 |
Novo Nordisk A/S |
Melanocortin receptor agonists
|
|
EP2633866A3
(en)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Combination therapy
|
|
US20100247540A1
(en)
*
|
2003-10-30 |
2010-09-30 |
Chemocentryx, Inc. |
Methods and Compositions For Modulating Angiogenesis
|
|
AU2004299058A1
(en)
*
|
2003-12-12 |
2005-06-30 |
Aventis Pharmaceutical, Inc. |
Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
|
|
MXPA06006837A
(es)
*
|
2003-12-15 |
2006-09-04 |
Theramex |
Derivados de 1-n-fenil-amino-ih-imidazol y composiciones farmaceuticas que los contienen.
|
|
DK1723128T3
(da)
|
2004-01-06 |
2013-02-18 |
Novo Nordisk As |
Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer
|
|
US7435831B2
(en)
*
|
2004-03-03 |
2008-10-14 |
Chemocentryx, Inc. |
Bicyclic and bridged nitrogen heterocycles
|
|
US7435830B2
(en)
*
|
2004-03-03 |
2008-10-14 |
Chemocentryx, Inc. |
Bicyclic and bridged nitrogen heterocycles
|
|
US20060003020A1
(en)
*
|
2004-03-11 |
2006-01-05 |
The Regents Of The University Of Michigan |
Anti-metastatic ability of mibefradil and gadolinium
|
|
EA200601743A1
(ru)
|
2004-03-19 |
2007-08-31 |
Йел Юниверсити |
Выделенный полипептид реналазы и его применение
|
|
WO2005092333A1
(en)
*
|
2004-03-22 |
2005-10-06 |
Myogen, Inc. |
(r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
|
|
EP1737448A1
(en)
*
|
2004-03-22 |
2007-01-03 |
Myogen, Inc. |
(s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
|
|
US7169807B2
(en)
*
|
2004-04-09 |
2007-01-30 |
Allergan, Inc. |
10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
|
|
CA2568622C
(en)
|
2004-06-01 |
2016-01-26 |
University Of Virginia Patent Foundation |
Dual small molecule inhibitors of cancer and angiogenesis
|
|
EP1765328B1
(en)
|
2004-06-14 |
2011-11-23 |
Zoser B. Salama |
Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody
|
|
US7740861B2
(en)
*
|
2004-06-16 |
2010-06-22 |
University Of Massachusetts |
Drug delivery product and methods
|
|
WO2006007213A1
(en)
*
|
2004-06-23 |
2006-01-19 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of pde-iii mediated diseases
|
|
WO2006002381A1
(en)
*
|
2004-06-24 |
2006-01-05 |
Wisconsin Alumni Research Foundation |
Neoglycorandomization and digitoxin analogs
|
|
US8507411B2
(en)
*
|
2004-06-24 |
2013-08-13 |
Wisconsin Alumni Research Foundation |
Neoglycorandomization and digitoxin analogs
|
|
EP1765785B1
(en)
*
|
2004-07-02 |
2009-07-08 |
Allergan, Inc. |
Prostaglandin analogs
|
|
JP2008508882A
(ja)
*
|
2004-08-03 |
2008-03-27 |
トランステック ファーマ,インコーポレイティド |
Rage融合タンパク質及び使用方法
|
|
US7906552B2
(en)
|
2004-08-10 |
2011-03-15 |
Allergan, Inc. |
Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
|
US7101904B2
(en)
*
|
2004-08-10 |
2006-09-05 |
Allergan, Inc. |
Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
|
US7183310B2
(en)
*
|
2004-08-10 |
2007-02-27 |
Allergan, Inc. |
Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
|
EP2494992A1
(en)
|
2004-08-24 |
2012-09-05 |
Merck Sharp & Dohme Corp. |
Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events
|
|
KR20070054246A
(ko)
|
2004-09-17 |
2007-05-28 |
유니버시티 오브 매사추세츠 |
리소좀성 효소 결핍을 위한 조성물 및 이의 용도
|
|
WO2006039252A2
(en)
*
|
2004-10-01 |
2006-04-13 |
Merck & Co., Inc. |
Compositions and methods for treating ophthalmic diseases
|
|
EP1647549A1
(en)
*
|
2004-10-14 |
2006-04-19 |
Laboratoire Theramex |
Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
|
|
US7612082B2
(en)
*
|
2004-10-28 |
2009-11-03 |
Allergan, Inc. |
Prostaglandin EP4 antagonists
|
|
US7101906B2
(en)
*
|
2004-11-16 |
2006-09-05 |
Allergan, Inc. |
2,3,4-substituted cyclopentanones as therapeutic agents
|
|
US7183324B2
(en)
|
2004-11-23 |
2007-02-27 |
Allergan, Inc. |
2,3,4-substituted cyclopentanones as therapeutic agents
|
|
US8148412B2
(en)
|
2004-12-03 |
2012-04-03 |
Novo Nordisk A/S |
Heteroaromatic glucokinase activators
|
|
US7091231B2
(en)
*
|
2004-12-10 |
2006-08-15 |
Allergan, Inc. |
12-Aryl prostaglandin analogs
|
|
CA2593545A1
(en)
*
|
2005-01-06 |
2006-07-13 |
Merck & Co., Inc. |
Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
|
|
DOP2006000008A
(es)
*
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
|
US7622583B2
(en)
|
2005-01-14 |
2009-11-24 |
Chemocentryx, Inc. |
Heteroaryl sulfonamides and CCR2
|
|
US20060173019A1
(en)
|
2005-01-14 |
2006-08-03 |
Solomon Ungashe |
Heteroaryl sulfonamides and CCR2
|
|
TWI386208B
(zh)
*
|
2005-04-18 |
2013-02-21 |
Allergan Inc |
治療性的經取代環戊酮
|
|
ES2434852T3
(es)
*
|
2005-04-21 |
2013-12-17 |
Chemocentryx, Inc. |
Anticuerpos que se unen a CCX-CKR2
|
|
CN101166527A
(zh)
|
2005-04-27 |
2008-04-23 |
艾尼纳制药公司 |
用于治疗肥胖症和糖尿病以及其相关病况和用于治疗可通过增加血液glp-1含量改善的病况的组合疗法
|
|
US8420628B2
(en)
*
|
2005-05-06 |
2013-04-16 |
Allergan, Inc. |
Substituted beta-lactams
|
|
EP1721615A1
(en)
|
2005-05-09 |
2006-11-15 |
Komipharm International Co., Ltd. |
Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
|
|
CA2609402C
(en)
|
2005-05-23 |
2014-10-21 |
Sdg, Inc. |
Lipid construct for delivery of insulin to a mammal
|
|
US20070203161A1
(en)
*
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
ES2651349T3
(es)
|
2005-06-08 |
2018-01-25 |
Rigel Pharmaceuticals, Inc. |
Composiciones y métodos para la inhibición de la ruta JAK
|
|
CN101505746A
(zh)
*
|
2005-06-17 |
2009-08-12 |
迪纳米斯治疗公司 |
炎症的治疗方法
|
|
US7777035B2
(en)
|
2005-06-22 |
2010-08-17 |
Chemocentryx, Inc. |
Azaindazole compounds and methods of use
|
|
MX2007016270A
(es)
|
2005-06-27 |
2008-03-05 |
Amgen Inc |
Compuestos aril nitrilo anti-inflamatorios.
|
|
US8039507B2
(en)
*
|
2005-06-29 |
2011-10-18 |
Allergan, Inc. |
Therapeutic substituted gamma lactams
|
|
EP2377856A1
(en)
|
2005-07-14 |
2011-10-19 |
Novo Nordisk A/S |
Urea glucokinase activators
|
|
US8937052B2
(en)
*
|
2005-07-27 |
2015-01-20 |
Alchemia Oncology Pty Limited |
Therapeutic protocols using hyaluronan
|
|
ATE518853T1
(de)
|
2005-08-12 |
2011-08-15 |
Schering Corp |
Verbindungen zur behandlung entzündlicher erkrankungen
|
|
EP1924606A4
(en)
|
2005-08-25 |
2010-01-13 |
Repair Technologies Inc |
DEVICES, COMPOSITIONS AND METHODS FOR PROTECTING AND REPAIRING CELLS AND TISSUE
|
|
US8871764B2
(en)
|
2005-08-29 |
2014-10-28 |
University Of Virginia Patent Foundation |
Lisofylline analogs and methods for use
|
|
JP5259408B2
(ja)
|
2005-08-29 |
2013-08-07 |
ユニバーシティ オブ バージニア パテント ファンデーション |
リソフィリン類縁体とその使用方法
|
|
AU2006289651B2
(en)
|
2005-09-07 |
2012-07-26 |
Alchemia Oncology Pty Limited |
Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
|
|
US20130131007A1
(en)
|
2005-09-07 |
2013-05-23 |
Bebaas, Inc. |
Vitamin b12 compositions
|
|
US20070178141A1
(en)
*
|
2005-09-07 |
2007-08-02 |
Bebaas, Inc. |
Vitamin B12 compositions
|
|
AU2006306228A1
(en)
*
|
2005-10-24 |
2007-05-03 |
University Of Massachusetts |
Compositions and their uses for gene therapy of bone conditions
|
|
AU2006311577B2
(en)
|
2005-11-09 |
2013-02-07 |
Zalicus Inc. |
Methods, compositions, and kits for the treatment of medical conditions
|
|
DE602006018057D1
(de)
|
2005-11-10 |
2010-12-16 |
Chemocentryx Inc |
Substituierte chinolone und verwendungsverfahren
|
|
US7427685B2
(en)
|
2005-12-06 |
2008-09-23 |
Allergan, Inc. |
Therapeutic substituted cyclopentanes
|
|
US7585895B2
(en)
*
|
2005-12-06 |
2009-09-08 |
Allergan, Inc. |
Therapeutic substituted cyclopentanes
|
|
WO2007073555A1
(en)
*
|
2005-12-20 |
2007-06-28 |
Gilead Colorado, Inc. |
Use of 4, 7-dihydrothieno [2, 3-b] pyridine compounds in the treatment of cardiovascular diseases
|
|
US7323477B2
(en)
*
|
2006-02-02 |
2008-01-29 |
Allergan, Inc. |
7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
|
|
WO2007098240A2
(en)
*
|
2006-02-21 |
2007-08-30 |
Astrum Therapeutics Pty. Ltd. |
Compositions to reduce blood glucose levels and treat diabetes
|
|
ES2622493T3
(es)
*
|
2006-02-24 |
2017-07-06 |
Rigel Pharmaceuticals, Inc. |
Composiciones y métodos para la inhibición de la ruta de JAK
|
|
EP1864692A1
(en)
*
|
2006-06-07 |
2007-12-12 |
Biotempt B.V. |
Use of peptides for the control of radiation injury
|
|
EP1996546B1
(en)
|
2006-03-20 |
2014-11-26 |
Allergan, Inc. |
Substituted gamma lactams as prostaglandin ep2 agonists
|
|
US20070225246A1
(en)
*
|
2006-03-27 |
2007-09-27 |
Denu John M |
O-acetyl-ADP-ribose non-hydrolyzable analogs
|
|
SG10201404220TA
(en)
*
|
2006-04-11 |
2014-10-30 |
Arena Pharm Inc |
Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
|
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
|
ES2437997T3
(es)
|
2006-04-14 |
2014-01-15 |
Prana Biotechnology Limited |
Método de tratamiento de la degeneración macular relacionada con la edad (AMD)
|
|
US20090016981A1
(en)
|
2006-05-03 |
2009-01-15 |
Allergan, Inc. |
Therapeutic compounds
|
|
US7439372B2
(en)
|
2006-05-03 |
2008-10-21 |
Allergan, Inc. |
Therapeutic compounds
|
|
US7476755B2
(en)
|
2006-05-04 |
2009-01-13 |
Allergan, Inc. |
Therapeutic compounds
|
|
GEP20115140B
(en)
|
2006-05-09 |
2011-01-10 |
Merck Sharp And Dome Corp |
Substituted spirocyclic cgrp receptor antagonists
|
|
US7547727B2
(en)
|
2006-05-22 |
2009-06-16 |
Allergan, Inc. |
Therapeutic cyclopentane derivatives
|
|
US7550448B2
(en)
*
|
2006-05-24 |
2009-06-23 |
Allergan, Inc. |
Therapeutic compounds
|
|
US7553860B2
(en)
*
|
2006-06-14 |
2009-06-30 |
Allergan, Inc. |
Substituted gamma lactams as therapeutic agents
|
|
DK2035390T3
(en)
|
2006-07-05 |
2016-01-04 |
Merial Inc |
1-aryl-5-alkylpyrazolderivatforbindelser, methods of making and methods of use thereof
|
|
AU2007272683B2
(en)
|
2006-07-10 |
2012-08-23 |
Allergan, Inc. |
Substituted cyclopentane derivatives as therapeutic agents
|
|
AU2007275873B2
(en)
|
2006-07-14 |
2012-06-14 |
Chemocentryx, Inc. |
Triazolyl phenyl benzenesulfonamides
|
|
US8519135B2
(en)
*
|
2006-07-14 |
2013-08-27 |
Chemocentryx, Inc. |
Heteroaryl sulfonamides and CCR2/CCR9
|
|
US7700627B2
(en)
*
|
2006-07-26 |
2010-04-20 |
Allergan, Inc. |
Therapeutic substituted lactams
|
|
US7625944B2
(en)
|
2006-07-31 |
2009-12-01 |
Activesite Pharmaceuticals, Inc. |
Inhibitors of plasma kallikrein
|
|
US7985767B2
(en)
*
|
2006-09-06 |
2011-07-26 |
Allergan, Inc. |
Therapeutic amides
|
|
EP2061760A1
(en)
|
2006-09-07 |
2009-05-27 |
Amgen, Inc |
Benzo-fused compounds for use in treating metabolic disorders
|
|
EP2076525A2
(en)
*
|
2006-10-06 |
2009-07-08 |
Wisconsin Alumni Research Foundation |
Colchicine neoglycosides and methods for their synthesis and use
|
|
EP2079728B1
(en)
|
2006-10-10 |
2013-09-25 |
Amgen Inc. |
N-aryl pyrazole compounds for use against diabetes
|
|
EP1920782A1
(en)
|
2006-11-10 |
2008-05-14 |
Glycotope Gmbh |
Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
|
|
WO2008073752A2
(en)
|
2006-12-11 |
2008-06-19 |
Allergan, Inc. |
Cyclobutyl derivatives for the treatment of glaucoma
|
|
GB0624757D0
(en)
|
2006-12-12 |
2007-01-17 |
Sosei R & D Ltd |
Novel compounds
|
|
WO2008077092A2
(en)
|
2006-12-19 |
2008-06-26 |
University Of Virginia Patent Foundation |
Combined effects of topiramate and ondansetron on alcohol consumption
|
|
US20080153808A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan, Inc. |
Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
|
|
US20120083508A1
(en)
|
2006-12-22 |
2012-04-05 |
Allergan, Inc. |
Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
|
|
US20080153874A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan Inc. |
Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
|
|
US20080153880A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan, Inc. |
Pan-alpha-2 receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
|
|
US20080153832A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan, Inc. |
Pan-alpha-2 receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
|
|
CA2673616A1
(en)
|
2006-12-22 |
2008-07-03 |
Allergan, Inc. |
Alpha-2b adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
|
|
US20080153825A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan Inc. |
Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders
|
|
US20080153927A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan, Inc. |
Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
|
|
US20080153881A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan, Inc. |
Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
|
|
WO2008082217A1
(en)
*
|
2006-12-28 |
2008-07-10 |
Lg Electronics Inc. |
Ice making system and method for ice making of refrigerator
|
|
AU2008204530B2
(en)
|
2007-01-11 |
2013-08-01 |
Vtv Therapeutics Llc |
Urea glucokinase activators
|
|
WO2008101060A1
(en)
*
|
2007-02-14 |
2008-08-21 |
Logical Therapeutics, Inc. |
Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and a proton pump inhibitor
|
|
JP2010520236A
(ja)
|
2007-02-28 |
2010-06-10 |
ユニバーシティ オブ バージニア パテント ファンデーション |
リソフィリンアナログとその使用法
|
|
WO2008141013A1
(en)
*
|
2007-05-08 |
2008-11-20 |
Allergan, Inc. |
S1p3 receptor inhibitors for treating pain
|
|
PL2639228T3
(pl)
|
2007-05-15 |
2017-01-31 |
Merial, Inc. |
Związki aryloazol-2-ilocyjanoetyloaminowe, sposób ich wytwarzania oraz sposób ich zastosowania
|
|
HUE032273T2
(en)
|
2007-05-22 |
2017-09-28 |
Chemocentryx Inc |
3-Imidazolyl-pyrazolo [3,4-b] pyridines
|
|
EP2170065A4
(en)
|
2007-06-20 |
2011-11-23 |
Merck Sharp & Dohme |
DIPHENYL SUBSTITUTED ALKANES
|
|
US7776877B2
(en)
|
2007-06-22 |
2010-08-17 |
Chemocentryx, Inc. |
N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
|
|
CA2692761C
(en)
|
2007-07-12 |
2013-04-30 |
Chemocentryx, Inc. |
Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation
|
|
US20100221334A1
(en)
*
|
2007-07-19 |
2010-09-02 |
Fink Mitchell P |
Compositions including leukotriene antagonists and nsaids and methods of using the same
|
|
GB2454290B
(en)
|
2007-08-07 |
2009-09-30 |
Prosarix Ltd |
Novel serotonergic modulators
|
|
US8962015B2
(en)
|
2007-09-28 |
2015-02-24 |
Sdg, Inc. |
Orally bioavailable lipid-based constructs
|
|
US8846053B2
(en)
|
2008-09-26 |
2014-09-30 |
Sdg, Inc. |
Orally bioavailable lipid-based constructs
|
|
WO2009052116A1
(en)
|
2007-10-15 |
2009-04-23 |
The Salk Institute For Biological Studies |
Methods for treating a variety of diseases and conditions, and compounds useful therefor
|
|
US8455548B2
(en)
*
|
2007-10-18 |
2013-06-04 |
Allergan, Inc. |
Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
|
|
US20100216857A1
(en)
*
|
2007-10-18 |
2010-08-26 |
Luhrs Lauren M B |
Method of treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
|
|
WO2009052075A2
(en)
*
|
2007-10-18 |
2009-04-23 |
Allergan, Inc. |
Method of treating motor disorders with alpha-2b adrenergic receptor agonists
|
|
US8389485B2
(en)
*
|
2007-10-29 |
2013-03-05 |
University Of Massachusetts |
Encapsulated nanoparticles for nucleic acid delivery
|
|
US8063033B2
(en)
|
2008-01-18 |
2011-11-22 |
Allergan, Inc. |
Therapeutic beta-lactams
|
|
US7956051B2
(en)
*
|
2008-01-24 |
2011-06-07 |
Allergan, Inc. |
Therapeutic amides and related compounds
|
|
US8633310B2
(en)
*
|
2008-02-19 |
2014-01-21 |
Allergan, Inc. |
Therapeutic substituted lactams
|
|
US8202855B2
(en)
|
2008-03-04 |
2012-06-19 |
Allergan, Inc |
Substituted beta-lactams
|
|
US7964596B2
(en)
|
2008-03-07 |
2011-06-21 |
Allergan, Inc. |
Therapeutic compounds
|
|
US20090233921A1
(en)
*
|
2008-03-11 |
2009-09-17 |
Allergan, Inc. |
Therapeutic cyclopentane derivatives
|
|
US7960379B2
(en)
*
|
2008-03-14 |
2011-06-14 |
Allergan, Inc. |
Therapeutic compounds
|
|
AU2009225747A1
(en)
*
|
2008-03-17 |
2009-09-24 |
Allergan, Inc. |
S1P3 receptor inhibitors for treating inflammation
|
|
US7732443B2
(en)
*
|
2008-03-18 |
2010-06-08 |
Yariv Donde |
Therapeutic substituted cyclopentanes
|
|
US7705001B2
(en)
*
|
2008-03-18 |
2010-04-27 |
Allergan, Inc |
Therapeutic substituted gamma lactams
|
|
US7960378B2
(en)
*
|
2008-03-18 |
2011-06-14 |
Allergan, Inc. |
Therapeutic compounds
|
|
US8198318B2
(en)
*
|
2008-03-18 |
2012-06-12 |
Allergen, Inc. |
Therapeutic amides
|
|
US7956055B2
(en)
*
|
2008-03-25 |
2011-06-07 |
Allergan, Inc. |
Substituted gamma lactams as therapeutic agents
|
|
EP2108960A1
(en)
*
|
2008-04-07 |
2009-10-14 |
Arena Pharmaceuticals, Inc. |
Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
|
|
US20090270398A1
(en)
*
|
2008-04-21 |
2009-10-29 |
Institute For Oneworld Health |
Compounds, Compositions and Methods Comprising Pyridazine Derivatives
|
|
US8207205B2
(en)
|
2008-04-21 |
2012-06-26 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising oxadiazole derivatives
|
|
US8236838B2
(en)
*
|
2008-04-21 |
2012-08-07 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising isoxazole derivatives
|
|
US20090264433A1
(en)
*
|
2008-04-21 |
2009-10-22 |
Institute For Oneworld Health |
Compounds, Compositions and Methods Comprising Triazine Derivatives
|
|
US7964634B2
(en)
*
|
2008-04-24 |
2011-06-21 |
Allergan, Inc. |
Therapeutic compounds
|
|
US7737140B2
(en)
*
|
2008-04-24 |
2010-06-15 |
Allergan, Inc. |
Therapeutic compounds
|
|
AU2009239381A1
(en)
|
2008-04-24 |
2009-10-29 |
Allergan, Inc. |
Substituted gamma lactams as therapeutic agents
|
|
EP2291368B1
(en)
*
|
2008-04-24 |
2012-12-19 |
Allergan, Inc. |
Substituted gamma lactams as therapeutic agents
|
|
CA2731279A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Allergan, Inc. |
Therapeutic compounds
|
|
WO2010033626A1
(en)
*
|
2008-09-19 |
2010-03-25 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising imidazole and triazole derivatives
|
|
EP2285790A1
(en)
*
|
2008-05-09 |
2011-02-23 |
Allergan, Inc. |
Therapeutic compounds
|
|
BRPI0912342A2
(pt)
*
|
2008-05-09 |
2015-10-06 |
Allergan Inc |
tiazolidinonas, oxazolidinonas substituídas terapêuticas, e compostos relacionados
|
|
US7981887B2
(en)
*
|
2008-05-09 |
2011-07-19 |
Allergan, Inc. |
Therapeutic compounds
|
|
JP2011519937A
(ja)
*
|
2008-05-09 |
2011-07-14 |
アラーガン インコーポレイテッド |
治療用n‐アリールまたはn‐ヘテロアリールピラゾリジンおよびピラゾリジノン誘導体
|
|
WO2009137343A1
(en)
|
2008-05-09 |
2009-11-12 |
Allergan, Inc. |
Therapeutic substituted hydantoins, and related compounds
|
|
US8530471B2
(en)
*
|
2008-05-09 |
2013-09-10 |
Allergan, Inc. |
Therapeutic cyclopentane derivatives
|
|
WO2009137412A1
(en)
*
|
2008-05-09 |
2009-11-12 |
Allergan, Inc. |
Therapeutic compounds
|
|
WO2009146255A1
(en)
*
|
2008-05-27 |
2009-12-03 |
Allergan, Inc. |
Prostaglandin produgs as hypotensive agents
|
|
US8252788B2
(en)
*
|
2008-05-20 |
2012-08-28 |
Allergan, Inc. |
Therapeutic compounds
|
|
EP2285775B1
(en)
*
|
2008-05-20 |
2017-03-22 |
Allergan, Inc. |
Lactams and their use in the treatment of inter alia ocular hypertension or baldness
|
|
AU2009257733A1
(en)
|
2008-06-12 |
2009-12-17 |
Merck Sharp & Dohme Corp. |
Branched 3- and 6-substituted quinolines as CGRP receptor antagonists
|
|
WO2010012650A1
(en)
|
2008-07-28 |
2010-02-04 |
Syddansk Universitet |
Compounds for the treatment of metabolic diseases
|
|
US20100022574A1
(en)
*
|
2008-07-28 |
2010-01-28 |
EndogenX, Inc. |
Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist
|
|
US8404736B2
(en)
|
2008-08-14 |
2013-03-26 |
Beta Pharma Canada Inc. |
Heterocyclic amide derivatives as EP4 receptor antagonists
|
|
JO2870B1
(en)
|
2008-11-13 |
2015-03-15 |
ميرك شارب اند دوهم كورب |
Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
|
|
EA019606B1
(ru)
|
2008-11-14 |
2014-04-30 |
Мериал Лимитед |
Арилоазол-2-илцианоэтиламино соединения противопаразитарного действия, обогащенные одним из энантиомеров
|
|
EP2186521A1
(en)
|
2008-11-14 |
2010-05-19 |
Mergemeier Steffen |
Compositons for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens and fragments thereof with polyvinylpyrrolidone and/or polyvinylpolypyrrolidone as therapeutically active compound
|
|
EP2550962B1
(en)
|
2008-11-19 |
2019-10-30 |
Boehringer Ingelheim Animal Health USA Inc. |
Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof
|
|
CN102223797A
(zh)
|
2008-11-21 |
2011-10-19 |
高点制药有限责任公司 |
金刚烷基苯甲酰胺化合物
|
|
TWI457347B
(zh)
|
2008-12-04 |
2014-10-21 |
Merial Ltd |
二聚合的阿佛菌素(avermectin)及密倍脈心(milbemycin)衍生物
|
|
EP3508477B1
(en)
|
2008-12-22 |
2021-11-10 |
ChemoCentryx, Inc. |
C5ar antagonists
|
|
PE20110924A1
(es)
|
2009-01-23 |
2011-12-24 |
Rigel Pharmaceuticals Inc |
Derivados de 2, 4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
|
|
CA2752156A1
(en)
|
2009-02-13 |
2010-08-19 |
Daniel W. Gil |
4-(1-(3-(hydroxymethyl)-2-methylphenyl)ethyl)-1h-imidazole-2(3h)-thione
|
|
WO2010093930A1
(en)
|
2009-02-13 |
2010-08-19 |
Allergan, Inc. |
Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
|
|
US8785468B2
(en)
|
2009-02-13 |
2014-07-22 |
Amgen Inc. |
Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
|
|
EA021076B1
(ru)
|
2009-02-24 |
2015-03-31 |
Мерк Шарп Энд Домэ Корп. |
Производные индола в качестве антагонистов рецептора crth2
|
|
GB0904044D0
(en)
|
2009-03-09 |
2009-04-22 |
Sosei R & D Ltd |
The treatment of inflammatory disorders and pain
|
|
WO2010103038A1
(en)
|
2009-03-11 |
2010-09-16 |
Novo Nordisk A/S |
Interleukin-21 variants having antagonistic binding to the il-21 receptor
|
|
US8511216B2
(en)
*
|
2009-03-30 |
2013-08-20 |
Kanzaki Kokyukoki Mfg. Co., Ltd. |
Hydraulic actuator unit
|
|
WO2010114997A1
(en)
|
2009-04-02 |
2010-10-07 |
Allergan, Inc. |
Prostaglandin e receptor antagonists
|
|
US8343976B2
(en)
*
|
2009-04-20 |
2013-01-01 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising pyrazole derivatives
|
|
EP3195896A1
(en)
|
2009-05-05 |
2017-07-26 |
Board of Regents, The University of Texas System |
Novel formulations of volatile anesthetics and methods of use for reducing inflammation
|
|
HUE052685T2
(hu)
|
2009-05-19 |
2021-05-28 |
Neuroderm Ltd |
Dopa-dekarboxiláz inhibitorok folyamatos adagolására szolgáló készítmények
|
|
BR112012001047A2
(pt)
*
|
2009-07-17 |
2019-09-24 |
Allergan Inc |
composições compreendendo um inibidor de colinesterase para tratar distúrbios cognitivos
|
|
EP2459195A1
(en)
*
|
2009-07-28 |
2012-06-06 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
IN2012DN01846A
(OSRAM)
|
2009-08-11 |
2015-08-21 |
Allergan Inc |
|
|
BR112012003573A2
(pt)
*
|
2009-08-20 |
2016-03-08 |
Twi Biotechnology Inc |
métodos para determinar uma eficácia de um composto para o tratamento de diabete e para diagnosticar diabete.
|
|
CA2772354A1
(en)
|
2009-08-26 |
2011-03-10 |
Daniel W. Gil |
Method of treating compulsive disorders with alpha-2b adrenergic receptor agonists
|
|
CA2771352A1
(en)
|
2009-09-02 |
2011-03-10 |
Merck Sharp & Dohme Corp. |
Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
|
US9889182B2
(en)
|
2009-09-15 |
2018-02-13 |
The Regents Of The University Of California |
Assisted enzyme replacement therapy
|
|
CN102574789B
(zh)
|
2009-09-21 |
2014-12-10 |
凯莫森特里克斯股份有限公司 |
吡咯烷酮甲酰胺衍生物作为趋化素-r(chemr23)调节剂
|
|
ES2467923T3
(es)
|
2009-09-30 |
2014-06-13 |
Transtech Pharma, Llc |
Derivados de imidazol substituidos para el tratamiento de la enfermedad de Alzheimer
|
|
BR112012012391A2
(pt)
|
2009-11-25 |
2020-10-20 |
Cytometix, Inc. |
análogos de ácido araquidônico e métodos para tratamento analgésico utilizando o mesmo
|
|
ES2546100T3
(es)
|
2009-12-04 |
2015-09-18 |
Merial, Inc. |
Compuestos pesticidas bis-organosulfurados
|
|
DK3078664T3
(da)
|
2009-12-17 |
2019-05-13 |
Merial Inc |
Antiparasitiske dihydroazol-sammensætninger
|
|
BR112012014933B1
(pt)
|
2009-12-17 |
2020-10-27 |
Merial, Inc. |
composições que compreendem compostos lactonas macrocíclicas e spirodioxepinoindóis
|
|
JP5540454B2
(ja)
*
|
2009-12-30 |
2014-07-02 |
シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド |
ジペプチジルペプチダーゼ阻害剤
|
|
US9090584B2
(en)
*
|
2010-01-26 |
2015-07-28 |
Allergan, Inc. |
Therapeutic agents for treatment of ocular hypertension
|
|
AU2011210352A1
(en)
|
2010-01-26 |
2012-08-09 |
Radikal Therapeutics Inc. |
Compositions and methods for prevention and treatment of pulmonary hypertension
|
|
US8299068B2
(en)
*
|
2010-01-29 |
2012-10-30 |
Allergan, Inc. |
Therapeutically active cyclopentanes
|
|
NZ602111A
(en)
|
2010-02-03 |
2014-10-31 |
Pharma Two B Ltd |
Extended release formulations of rasagiline and uses thereof
|
|
GB201002530D0
(en)
|
2010-02-15 |
2010-03-31 |
Univ Wolverhampton The |
Di-aspirin derivatives
|
|
TWI510241B
(zh)
*
|
2010-02-18 |
2015-12-01 |
Vtv Therapeutice Llc |
苯基-雜芳基衍生物及其使用方法
|
|
EP2538783B1
(en)
|
2010-02-22 |
2016-06-01 |
Merck Sharp & Dohme Corp. |
Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
|
SG184243A1
(en)
|
2010-03-30 |
2012-10-30 |
Verseon Corp |
Multisubstituted aromatic compounds as inhibitors of thrombin
|
|
UA108641C2
(uk)
|
2010-04-02 |
2015-05-25 |
|
Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування
|
|
WO2011130716A2
(en)
|
2010-04-16 |
2011-10-20 |
Access Pharmaceuticals, Inc. |
A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
|
|
US20110288093A1
(en)
|
2010-04-20 |
2011-11-24 |
Institute For Oneworld Health |
Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives
|
|
EP2560643A1
(en)
|
2010-04-20 |
2013-02-27 |
Institute for OneWorld Health |
Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives
|
|
US20130116284A1
(en)
|
2010-05-10 |
2013-05-09 |
Radikal Therapeutics Inc. |
Lipoic acid and nitroxide derivatives and uses thereof
|
|
WO2011146358A1
(en)
|
2010-05-21 |
2011-11-24 |
Merck Sharp & Dohme Corp. |
Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
|
JP5902676B2
(ja)
|
2010-05-26 |
2016-04-13 |
ブイティーブイ セラピューティクス リミティド ライアビリティ カンパニー |
グルコキナーゼ活性化因子と組み合わせたメトホルミンの使用、及びメトホルミン及びグルコキナーゼ活性化因子を含む組成物
|
|
US9193989B2
(en)
|
2010-06-18 |
2015-11-24 |
Taiho Pharmaceutical Co., Ltd. |
PRPK-TPRKB modulators and uses thereof
|
|
AU2011270872A1
(en)
|
2010-06-24 |
2013-01-31 |
Allergan, Inc. |
Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
|
|
DK2585064T3
(en)
|
2010-06-24 |
2017-07-24 |
Chemocentryx Inc |
C5aR antagonists
|
|
US8492424B2
(en)
|
2010-07-01 |
2013-07-23 |
Allergan, Inc. |
Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
|
|
US8859606B2
(en)
|
2010-07-01 |
2014-10-14 |
Allergan, Inc. |
Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
|
|
WO2012003145A2
(en)
|
2010-07-02 |
2012-01-05 |
Allergan, Inc. |
Therapeutic agents for ocular hypertension
|
|
US9714238B2
(en)
|
2010-07-02 |
2017-07-25 |
Allergan, Inc. |
Therapeutic agents for ocular hypertension
|
|
NZ605709A
(en)
|
2010-07-02 |
2014-08-29 |
Univ Virginia Patent Found |
Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
|
|
CN103201280B
(zh)
|
2010-07-28 |
2016-08-10 |
里格尔药品股份有限公司 |
抑制jak途径的组合物和方法
|
|
BR112013002846A2
(pt)
|
2010-08-05 |
2016-06-07 |
Conrig Pharma Aps |
derivados de tandospirona deuterada como agonista do receptor de 5-ht1a
|
|
KR102013086B1
(ko)
|
2010-08-16 |
2019-08-21 |
알러간, 인코포레이티드 |
알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법
|
|
ES2485373T3
(es)
|
2010-08-20 |
2014-08-13 |
Allergan, Inc. |
Compuestos que actúan en múltiples receptores de prostaglandina proporcionando una respuesta anti-inflamatoria general
|
|
WO2012032513A1
(en)
|
2010-09-07 |
2012-03-15 |
Bar-Ilan University |
Boranophosphate derivatives for the treatment of osteoarthritis
|
|
WO2012032524A1
(en)
|
2010-09-09 |
2012-03-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd |
Near infrared fluorescent particles and uses thereof
|
|
GB201016880D0
(en)
|
2010-10-07 |
2010-11-17 |
Riotech Pharmaceuticals Ltd |
Phosphodiesterase inhibitors
|
|
SI2627328T1
(sl)
|
2010-10-15 |
2017-01-31 |
Contera Pharma Aps |
Kombinacije agonistov receptorjev serotonina za zdravljenje motenj premikanja
|
|
US20130315934A1
(en)
|
2010-10-28 |
2013-11-28 |
Yale University |
Methods and Compositions for Assessing and Treating Cancer
|
|
WO2012059932A1
(en)
|
2010-11-01 |
2012-05-10 |
Aurigene Discovery Technologies Limited |
2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
|
|
TWI522355B
(zh)
|
2010-11-12 |
2016-02-21 |
默沙東藥廠 |
六氫吡啶酮甲醯胺氮雜茚滿cgrp受體拮抗劑
|
|
SI2640358T1
(en)
|
2010-11-15 |
2018-05-31 |
Neuroderm Ltd. |
Continuous administration of L-dopa, dopamine decarboxylase inhibitors, catechol-O-methyl transferase inhibitors, and compositions thereof
|
|
CA2818563C
(en)
|
2010-11-16 |
2019-11-12 |
Merial Limited |
Monensin derivatives for the treatment and prevention of protozoal infections.
|
|
US9308255B2
(en)
|
2010-11-24 |
2016-04-12 |
Yale University |
Methods of administering D-dopachrome tautomerase (D-DT) to treat ischemia-reperfusion injury
|
|
WO2012070040A1
(en)
|
2010-11-26 |
2012-05-31 |
Technion Research And Development Foundation Ltd |
Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury
|
|
WO2012074785A1
(en)
|
2010-12-03 |
2012-06-07 |
Allergan, Inc. |
Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
|
|
EP2648754A4
(en)
|
2010-12-07 |
2016-02-24 |
Philadelphia Health & Educatio |
METHOD OF INHIBITING CANCER METASTASES
|
|
GB201020860D0
(en)
|
2010-12-09 |
2011-01-26 |
Univ Wolverhampton |
Disulfiram formulation and uses thereof
|
|
HRP20190096T1
(hr)
|
2010-12-15 |
2019-02-22 |
Contravir Pharmaceuticals, Inc. |
Molekule analoga ciklosporina modificirani na amino kiselini 1 i 3
|
|
US8895572B2
(en)
|
2010-12-22 |
2014-11-25 |
Merck Sharp & Dohme Corp. |
Fused heterocyclic indane carboxamide CGRP receptor antagonists
|
|
WO2012093383A1
(en)
|
2011-01-04 |
2012-07-12 |
Radikal Therapeutics Inc. |
Compositions and methods for treatment of sepsis and related conditions
|
|
US11759441B2
(en)
|
2011-01-07 |
2023-09-19 |
Anji Pharmaceuticals Inc. |
Biguanide compositions and methods of treating metabolic disorders
|
|
SG191855A1
(en)
|
2011-01-07 |
2013-08-30 |
Elcelyx Therapeutics Inc |
Chemosensory receptor ligand-based therapies
|
|
US9211263B2
(en)
|
2012-01-06 |
2015-12-15 |
Elcelyx Therapeutics, Inc. |
Compositions and methods of treating metabolic disorders
|
|
US11974971B2
(en)
|
2011-01-07 |
2024-05-07 |
Anji Pharmaceuticals Inc. |
Compositions and methods for treating metabolic disorders
|
|
US8796338B2
(en)
|
2011-01-07 |
2014-08-05 |
Elcelyx Therapeutics, Inc |
Biguanide compositions and methods of treating metabolic disorders
|
|
US9480663B2
(en)
|
2011-01-07 |
2016-11-01 |
Elcelyx Therapeutics, Inc. |
Biguanide compositions and methods of treating metabolic disorders
|
|
US9572784B2
(en)
|
2011-01-07 |
2017-02-21 |
Elcelyx Therapeutics, Inc. |
Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
|
|
MX339243B
(es)
|
2011-02-03 |
2016-05-18 |
Vtv Therapeutics Llc |
Derivados fusionados sustituidos de imidazol, composiciones farmaceuticas y metodos de uso de los mismos.
|
|
US20120231069A1
(en)
|
2011-03-08 |
2012-09-13 |
Access Pharmaceuticals, Inc. |
Targeted Nanocarrier Systems for Delivery of Actives Across Biological Membranes
|
|
DK2683385T3
(en)
|
2011-03-10 |
2018-09-17 |
Rigel Pharmaceuticals Inc |
2,4-SUBSTITUTED PYRIMIDINE DIAMINES FOR DISKOID LUPUS USE
|
|
US8476221B2
(en)
|
2011-03-18 |
2013-07-02 |
Halimed Pharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders
|
|
KR101606250B1
(ko)
|
2011-03-23 |
2016-03-24 |
암젠 인크 |
Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
|
|
US9127027B2
(en)
|
2011-04-06 |
2015-09-08 |
The Medical College Of Wisconsin, Inc. |
Epoxyeicosatrienoic acid analogs and methods of making and using the same
|
|
EP2694465A4
(en)
|
2011-04-08 |
2015-03-18 |
Univ Syddansk |
SUBSTITUTED ORTHOFLUOR COMPOUNDS FOR THE TREATMENT OF METABOLISM DISEASES
|
|
WO2012140647A2
(en)
|
2011-04-11 |
2012-10-18 |
Yeda Research And Development Co. Ltd |
Albumin binding probes and drug conjugates thereof
|
|
US8691861B2
(en)
|
2011-04-13 |
2014-04-08 |
Activesite Pharmaceuticals, Inc. |
Prodrugs of inhibitors of plasma kallikrein
|
|
WO2012143377A1
(en)
|
2011-04-18 |
2012-10-26 |
Max-Delbrück-Centrum für Molekulare Medizin |
Niclosamide for the treatment of cancer metastasis
|
|
AU2012250776B2
(en)
|
2011-05-04 |
2017-06-15 |
Balance Therapeutics, Inc. |
Pentylenetetrazole derivatives
|
|
KR20140048881A
(ko)
|
2011-05-09 |
2014-04-24 |
유니버시티 오브 버지니아 페이턴트 파운데이션 |
암 치료 조성물 및 방법
|
|
EP2714028A1
(en)
|
2011-05-27 |
2014-04-09 |
Allergan, Inc. |
D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders
|
|
EP2714040A1
(en)
|
2011-06-01 |
2014-04-09 |
Concit Pharma ApS |
Combinations of serotonin receptor agonists for treatment of movement disorders
|
|
AU2012271562A1
(en)
|
2011-06-17 |
2014-01-30 |
Allergan, Inc. |
D -serine for the treatment of visual system disorders
|
|
WO2013003168A1
(en)
|
2011-06-27 |
2013-01-03 |
Merial Limited |
Novel insect-repellent coumarin derivatives, syntheses, and methods of use
|
|
ES2618813T3
(es)
|
2011-06-27 |
2017-06-22 |
Merial, Inc. |
Compuestos y composiciones de éter amido-piridílico y uso contra los parásitos
|
|
WO2013005216A1
(en)
|
2011-07-05 |
2013-01-10 |
Radikal Therapeutics Inc. |
Compositions and methods for treatment of renal ischemia-reperfusion injury
|
|
EP2736906B1
(en)
|
2011-07-25 |
2016-10-19 |
Allergan, Inc. |
N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS
|
|
US8609658B2
(en)
|
2011-07-27 |
2013-12-17 |
Allergan, Inc. |
N,N-dialkylalkylenyl esters, compositions thereof, and methods for use thereof
|
|
WO2013019169A1
(en)
|
2011-08-01 |
2013-02-07 |
Institute For Oneworld Health |
Phosphate prodrugs
|
|
EP2763540A4
(en)
|
2011-09-09 |
2015-04-22 |
Univ Yale |
COMPOSITIONS AND METHODS FOR THE EVALUATION AND TREATMENT OF INFLAMMATORY DISEASES AND DISEASES
|
|
CA2848211A1
(en)
|
2011-09-09 |
2013-03-14 |
University Of Virginia Patent Foundation |
Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
|
|
EP2758377B1
(en)
|
2011-09-22 |
2017-08-02 |
Merck Sharp & Dohme Corp. |
Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
|
|
US9096598B2
(en)
|
2011-10-03 |
2015-08-04 |
Merck Sharp & Dohme Corp. |
Azaindoles as Janus kinase inhibitors
|
|
US10980798B2
(en)
|
2011-11-03 |
2021-04-20 |
Taiwan Liposome Company, Ltd. |
Pharmaceutical compositions of hydrophobic camptothecin derivatives
|
|
TWI480042B
(zh)
|
2011-11-03 |
2015-04-11 |
Taiwan Liposome Co Ltd |
疏水性喜樹鹼衍生物之醫藥組合物
|
|
BR112014011775A8
(pt)
|
2011-11-17 |
2017-07-11 |
Merial Ltd |
Composições compreendendo um aril pirazol e um imidazol substituído, métodos e usos dos mesmos
|
|
CN103202863A
(zh)
|
2011-11-18 |
2013-07-17 |
善笙生物科技股份有限公司 |
一种用于预防或改善关节炎症状的药物组合物及其应用
|
|
CA2856507C
(en)
|
2011-11-21 |
2017-03-21 |
Allergan, Inc. |
Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
|
|
CA2856831C
(en)
|
2011-12-01 |
2020-02-18 |
Chemocentryx, Inc. |
Substituted benzimidazoles and benzopyrazoles as ccr(4) antagonists
|
|
WO2013082490A1
(en)
|
2011-12-01 |
2013-06-06 |
Chemocentryx, Inc. |
Substituted anilines as ccr(4) antagonists
|
|
EP2785719B1
(en)
|
2011-12-02 |
2017-11-08 |
Merial, Inc. |
Long-acting injectable moxidectin formulations and novel moxidectin crystal forms
|
|
EP2788000B1
(en)
|
2011-12-06 |
2018-05-30 |
Merck Sharp & Dohme Corp. |
Pyrrolopyrimidines as janus kinase inhibitors
|
|
JP6132851B2
(ja)
|
2011-12-21 |
2017-05-24 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
一般的な抗炎症反応を与える複数のプロスタグランジン受容体において作用する化合物
|
|
JP6124187B2
(ja)
|
2011-12-21 |
2017-05-10 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
一般的な抗炎症反応を与える複数のプロスタグランジン受容体において作用する化合物
|
|
CA2862263C
(en)
|
2011-12-27 |
2016-09-06 |
Allergan, Inc. |
Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
|
|
EP2966064A1
(en)
|
2011-12-27 |
2016-01-13 |
Allergan, Inc. |
Pyrazole-3-carboxylic acid compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
|
|
NZ626578A
(en)
|
2012-01-06 |
2016-11-25 |
Elcelyx Therapeutics Inc |
Compositions and methods for treating metabolic disorders
|
|
ES2832773T3
(es)
|
2012-01-06 |
2021-06-11 |
Anji Pharma Us Llc |
Composiciones de biguanida y métodos de tratamiento de trastornos metabólicos
|
|
EP2814485A4
(en)
|
2012-02-17 |
2015-08-26 |
Merck Sharp & Dohme |
DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
|
|
KR102083693B1
(ko)
|
2012-02-29 |
2020-03-02 |
케모센트릭스, 인크. |
Ccr9 길항제로써 피라졸-1-일 벤젠 술폰아미드
|
|
JP6231548B2
(ja)
|
2012-03-23 |
2017-11-15 |
マテオン セラピューティクス, インコーポレイテッド |
カテプシンの阻害のための組成物および方法
|
|
WO2013151982A1
(en)
|
2012-04-03 |
2013-10-10 |
Arena Pharmaceuticals, Inc. |
Methods and compounds useful in treating pruritus, and methods for identifying such compounds
|
|
JP2015519309A
(ja)
|
2012-04-16 |
2015-07-09 |
カネック ファーマ インコーポレイテッド |
Ptp−1bインヒビター前駆体としての縮合芳香族ホスホナート誘導体
|
|
EP2838519B1
(en)
|
2012-04-17 |
2017-11-22 |
University College Dublin National University Of Ireland, Dublin |
Methods and compounds for treating proliferative disorders and viral infections
|
|
US9388127B2
(en)
|
2012-04-17 |
2016-07-12 |
University College Dublin, National University Of Ireland, Dublin |
Thromboxane receptor antagonists
|
|
CN104411301B
(zh)
|
2012-04-18 |
2018-02-06 |
康特拉医药公司 |
适于改善运动障碍治疗的口服药物配方
|
|
US9227972B2
(en)
|
2012-05-09 |
2016-01-05 |
Merck Sharp & Dohme Corp. |
Aliphatic spirolactam CGRP receptor antagonists
|
|
US9296750B2
(en)
|
2012-05-09 |
2016-03-29 |
Merck Sharp & Dohme Corp. |
Spirolactam CGRP receptor antagonists
|
|
WO2013169563A1
(en)
|
2012-05-09 |
2013-11-14 |
Merck Sharp & Dohme Corp. |
Pyridine cgrp receptor antagonists
|
|
US20130310340A1
(en)
|
2012-05-16 |
2013-11-21 |
Rigel Pharmaceuticals, Inc. |
Method of treating muscular degradation
|
|
US20150368197A1
(en)
|
2012-06-21 |
2015-12-24 |
Radikal Therapeutics Ins. |
Compositions and methods for treatment of inflammatory diseases of the lung
|
|
US20140024621A1
(en)
|
2012-07-23 |
2014-01-23 |
Ms Therapeutics Limited |
Aminopyridine compounds and their uses
|
|
EP2874622A4
(en)
|
2012-07-23 |
2015-12-30 |
Merck Sharp & Dohme |
TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
|
|
CN107184569A
(zh)
|
2012-08-09 |
2017-09-22 |
迪纳米斯治疗公司 |
保持或改善对象健康、幸福和/或生理功能的方法
|
|
US9505749B2
(en)
|
2012-08-29 |
2016-11-29 |
Amgen Inc. |
Quinazolinone compounds and derivatives thereof
|
|
EP2895172B1
(en)
|
2012-09-12 |
2019-02-06 |
Rigel Pharmaceuticals, Inc. |
Treatment for vitiligo
|
|
CN104822702B
(zh)
|
2012-10-19 |
2019-07-30 |
Txp制药股份有限公司 |
α-MSH和γ-MSH类似物
|
|
US9938281B2
(en)
|
2012-11-16 |
2018-04-10 |
Merck Sharp & Dohme Corp. |
Purine inhibitors of human phosphatidylinositol 3-kinase delta
|
|
BR112015011441A2
(pt)
|
2012-11-20 |
2017-07-11 |
Merial Inc |
composições e compostos antihelmínticos e métodos de usos dos mesmos
|
|
EP2928474B1
(en)
|
2012-12-07 |
2018-11-14 |
ChemoCentryx, Inc. |
Diazole lactams
|
|
JP6306607B2
(ja)
|
2012-12-21 |
2018-04-04 |
ケモセントリックス,インコーポレイティド |
ジアゾールアミド
|
|
JP6403688B2
(ja)
|
2013-01-21 |
2018-10-10 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
全身性抗炎症反応を提供する複数のプロスタグランジン受容体で作用する化合物
|
|
US20140213555A1
(en)
|
2013-01-25 |
2014-07-31 |
Rigel Pharmaceuticals, Inc. |
Compounds and method for treating autoimmune diseases
|
|
WO2014134774A1
(en)
|
2013-03-04 |
2014-09-12 |
Merck Sharp & Dohme Corp. |
Compounds inhibiting leucine-rich repeat kinase enzyme activity
|
|
KR20160005330A
(ko)
|
2013-03-05 |
2016-01-14 |
라디칼 쎄라퓨틱스 인코포레이티드 |
다기능 질소산화물 유도체의 프로드럭 및 그의 용도
|
|
KR102209353B1
(ko)
|
2013-03-13 |
2021-01-29 |
뉴로덤 엘티디 |
파킨슨 병 치료 방법
|
|
AU2014239641B2
(en)
|
2013-03-14 |
2016-10-20 |
Alkermes Pharma Ireland Limited |
Prodrugs of fumarates and their use in treating various diseases
|
|
SI2968297T1
(sl)
|
2013-03-15 |
2019-02-28 |
Verseon Corporation |
Multisubstituirane aromatske skupine kot inhibitorji serinske proteaze
|
|
HK1214252A1
(zh)
|
2013-03-15 |
2016-07-22 |
Verseon Corporation |
作為凝血酶抑制劑的鹵代吡唑
|
|
US9051294B2
(en)
|
2013-04-30 |
2015-06-09 |
Allergan, Inc. |
Therapeutic agents
|
|
WO2014194209A1
(en)
|
2013-05-31 |
2014-12-04 |
Allergan, Inc. |
Substituted cyclopentenes as therapeutic agents
|
|
ES2769893T3
(es)
|
2013-07-02 |
2020-06-29 |
Ecoplanet Env Llc |
Formulaciones de compuestos orgánicos volátiles que tienen actividad antimicrobiana
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
EP3035800B1
(en)
|
2013-08-22 |
2019-10-09 |
Merck Sharp & Dohme Corp. |
Compounds inhibiting leucine-rich repeat kinase enzyme activity
|
|
TWI622406B
(zh)
|
2013-10-23 |
2018-05-01 |
善笙生物科技股份有限公司 |
來自牛樟芝菌絲體的化合物及混合物的用途
|
|
US9315486B2
(en)
|
2013-10-29 |
2016-04-19 |
Allergan, Inc. |
Therapeutic cyclopentanols, compositions thereof, and methods for use thereof
|
|
NZ719916A
(en)
|
2013-11-01 |
2017-09-29 |
Merial Inc |
Antiparasitic and pesticidal isoxazoline compounds
|
|
WO2015073344A1
(en)
|
2013-11-14 |
2015-05-21 |
Merck Sharp & Dohme Corp. |
Compounds inhibiting leucine-rich repeat kinase enzyme activity
|
|
CN105960237B
(zh)
|
2013-12-02 |
2020-03-31 |
凯莫森特里克斯股份有限公司 |
Ccr6化合物
|
|
US9388153B2
(en)
|
2013-12-20 |
2016-07-12 |
Allergan, Inc. |
Secondary amines as therapeutic agents
|
|
WO2015113057A1
(en)
|
2014-01-27 |
2015-07-30 |
Allergan, Inc. |
Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation
|
|
US11717515B2
(en)
|
2020-12-22 |
2023-08-08 |
Allergan Pharmaceuticals International Limited |
Treatment of migraine
|
|
US12168004B2
(en)
|
2014-02-05 |
2024-12-17 |
Merck Sharp & Dohme Llc |
Treatment of migraine
|
|
HK1232218A1
(zh)
|
2014-02-05 |
2018-01-05 |
Merck Sharp & Dohme Llc |
Cgrp-活性化合物的片剂制剂
|
|
US10258585B2
(en)
|
2014-03-13 |
2019-04-16 |
Neuroderm, Ltd. |
DOPA decarboxylase inhibitor compositions
|
|
PL3116475T3
(pl)
|
2014-03-13 |
2021-02-08 |
Neuroderm Ltd |
Kompozycje inhibitora dekarboksylazy dopa
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
AU2015249540B2
(en)
|
2014-04-22 |
2019-08-22 |
Txp Pharma Gmbh |
Peptide analogues with branched amino acid probe(s)
|
|
WO2015162483A1
(en)
|
2014-04-22 |
2015-10-29 |
Txp Pharma Gmbh |
Alpha- and gamma-msh analogues
|
|
WO2015162486A1
(en)
|
2014-04-22 |
2015-10-29 |
Txp Pharma Gmbh |
Linear gamma msh with c- and / or n-terminal extensions of lysine and / or glutamic acid residues
|
|
US9394273B2
(en)
|
2014-05-15 |
2016-07-19 |
Allergan, Inc. |
Therapeutic prostaglandin receptor agonists
|
|
CN106536518B
(zh)
|
2014-05-19 |
2020-05-12 |
勃林格殷格翰动物保健美国公司 |
驱蠕虫化合物
|
|
WO2015179815A1
(en)
|
2014-05-22 |
2015-11-26 |
Allergan, Inc. |
Amidoalkylenyl and amidoaryl esters, compositions thereof, and methods for their use
|
|
KR101636758B1
(ko)
*
|
2014-05-30 |
2016-07-06 |
디씨에스이엔지 주식회사 |
회전속도비를 이용하여 회전체내 절삭툴을 제어할 수 있는 오비탈식 파이프 절삭장치
|
|
KR20170010059A
(ko)
|
2014-06-06 |
2017-01-25 |
알러간, 인코포레이티드 |
치료적 화합물로서 신규한 ep4 작용제
|
|
US9908923B2
(en)
|
2014-06-11 |
2018-03-06 |
The Medical College Of Wisconsin, Inc. |
Monomeric CXCL121 peptide and methods of use thereof
|
|
WO2016009341A1
(en)
|
2014-07-14 |
2016-01-21 |
Radikal Therapeutics Inc. |
Thioredoxin mimetic prodrugs and uses thereof
|
|
GB201417828D0
(en)
|
2014-10-08 |
2014-11-19 |
Cereno Scient Ab |
New methods and compositions
|
|
US10954240B2
(en)
|
2014-09-03 |
2021-03-23 |
Merck Sharp & Dohme Corp. |
Compounds inhibiting leucine-rich repeat kinase enzyme activity
|
|
KR20170048410A
(ko)
|
2014-09-17 |
2017-05-08 |
베르선 코포레이션 |
세린 프로테아제 저해제로서의 피라졸릴-치환된 피리돈 화합물
|
|
IL292655B2
(en)
|
2014-10-06 |
2024-03-01 |
Chemocentryx Inc |
CCR9 chemokine receptor inhibitor for use in a method for treating or reducing the development of inflammatory bowel diseases
|
|
BR112017011335A2
(pt)
|
2014-12-02 |
2018-02-20 |
Prana Biotechnology Limited |
compostos de 4h-pirido[1,2-a]pirimidin-4-ona
|
|
WO2016092546A1
(en)
|
2014-12-09 |
2016-06-16 |
Ezekiel Golan |
Binge behavior regulators
|
|
US9899696B2
(en)
*
|
2015-01-21 |
2018-02-20 |
Lockheed Martin Advanced Energy Storage, Llc |
Solid buffer materials for electrolyte solutions and flow batteries utilizing same
|
|
PT3258962T
(pt)
|
2015-02-20 |
2023-02-16 |
Univ Leland Stanford Junior |
Composições mistas de alergénios e métodos para a utilização das mesmas
|
|
KR102824411B1
(ko)
|
2015-02-27 |
2025-06-23 |
베르선 코포레이션 |
세린 프로테아제 저해제로서의 치환된 피라졸 화합물
|
|
SG11201707276PA
(en)
|
2015-03-09 |
2017-10-30 |
Intekrin Therapeutics Inc |
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
|
|
EP4414028A3
(en)
|
2015-05-19 |
2024-11-27 |
Yale University |
Compositions for treating pathological calcification conditions, and methods using same
|
|
MX379719B
(es)
|
2015-05-20 |
2025-03-11 |
Boehringer Ingelheim Animal Health Usa Inc |
Compuestos depsipeptidicos como anthelmínticos.
|
|
JP6356364B1
(ja)
|
2015-05-20 |
2018-07-11 |
アムジエン・インコーポレーテツド |
Apj受容体のトリアゾールアゴニスト
|
|
US11571462B2
(en)
|
2015-06-03 |
2023-02-07 |
The Medical College Of Wisconsin, Inc. |
Engineered CCL20 locked dimer polypeptide
|
|
CA2988086C
(en)
|
2015-06-03 |
2023-09-19 |
The Medical College Of Wisconsin, Inc. |
An engineered ccl20 locked dimer polypeptide
|
|
DK3307296T3
(da)
|
2015-06-15 |
2021-12-13 |
Univ Leland Stanford Junior |
Timp2 til anvendelse til behandling af aldringsassocierede tilstande
|
|
CA2988593C
(en)
|
2015-06-16 |
2023-10-24 |
Nanophagix LLC |
Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
|
|
ES2858551T3
(es)
|
2015-06-16 |
2021-09-30 |
Atxa Therapeutics Ltd |
Antagonistas del receptor de tromboxano
|
|
US10631564B2
(en)
|
2015-06-19 |
2020-04-28 |
University Of Southern California |
Enterically coated microparticle compositions and methods for modified nutrient delivery
|
|
US10744070B2
(en)
|
2015-06-19 |
2020-08-18 |
University Of Southern California |
Enteral fast access tract platform system
|
|
JP6731427B2
(ja)
|
2015-06-30 |
2020-07-29 |
ネウラッド リミテッドNeurad Ltd. |
新規の呼吸制御調節化合物、およびこれを製造し、かつ使用する方法
|
|
WO2017007835A1
(en)
|
2015-07-07 |
2017-01-12 |
Nanobio Corporation |
Methods and compositions for nanoemulsion vaccine formulations
|
|
WO2017025951A1
(en)
|
2015-08-10 |
2017-02-16 |
Ramot At Tel-Aviv University Ltd. |
Pillararenes and uses thereof
|
|
US11497813B2
(en)
|
2015-11-02 |
2022-11-15 |
Biovinc, Llc |
Bortezomib conjugates and methods using same
|
|
WO2017077528A2
(en)
|
2015-11-02 |
2017-05-11 |
Salzman Lovelace Investments, Ltd. |
Methods and pharmaceutical compositions for treatment of lung inflammation
|
|
WO2017079260A1
(en)
|
2015-11-02 |
2017-05-11 |
University Of Rochester |
Phosphonate-chloroquine conjugates and methods using same
|
|
TWI724056B
(zh)
|
2015-11-19 |
2021-04-11 |
美商卡默森屈有限公司 |
Cxcr2抑制劑
|
|
TWI734715B
(zh)
|
2015-11-19 |
2021-08-01 |
美商卡默森屈有限公司 |
趨化因子受體調節劑
|
|
WO2017087936A1
(en)
|
2015-11-20 |
2017-05-26 |
Yale University |
Compositions for treating ectopic calcification disorders, and methods using same
|
|
MA43872A
(fr)
|
2016-01-14 |
2021-05-19 |
Chemocentryx Inc |
Procédé de traitement d'une glomérulopathie à c3
|
|
ES2985738T3
(es)
|
2016-01-20 |
2024-11-07 |
Chemocentryx Inc |
Compuestos de 2-oxindol
|
|
JP7003045B2
(ja)
|
2016-02-11 |
2022-02-04 |
シェヴィオン モデハイ |
神経変性の治療のための方法及び医薬組成物
|
|
UY37137A
(es)
|
2016-02-24 |
2017-09-29 |
Merial Inc |
Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
|
|
WO2017153977A1
(en)
|
2016-03-08 |
2017-09-14 |
Salzman Lovelace Investments, Ltd. |
Solid formulations of resolvins and uses thereof
|
|
WO2017176620A2
(en)
|
2016-04-04 |
2017-10-12 |
Chemocentryx, Inc. |
SOLUBLE C5aR ANTAGONISTS
|
|
US10946020B2
(en)
|
2016-04-06 |
2021-03-16 |
University Of Virginia Patent Foundation |
Compositions and methods for treating cancer
|
|
EP3452466B1
(en)
|
2016-05-03 |
2020-08-12 |
Amgen Inc. |
Heterocyclic triazole compounds as agonists of the apj receptor
|
|
WO2017201390A1
(en)
|
2016-05-19 |
2017-11-23 |
The Regents Of The University Of Michigan |
Novel adjuvant compositions
|
|
US10036024B2
(en)
|
2016-06-03 |
2018-07-31 |
Purdue Research Foundation |
siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
|
|
EP4094778B1
(en)
|
2016-06-03 |
2024-05-15 |
Novacyte Therapeutics Company.,LTD |
Polymer linkers and their uses
|
|
ES2979332T3
(es)
|
2016-06-27 |
2024-09-25 |
Chemocentryx Inc |
Compuestos inmunomoduladores
|
|
KR102443161B1
(ko)
|
2016-07-11 |
2022-09-14 |
콘테라 파르마 에이/에스 |
아침 운동 불능을 치료하기 위한 박동성 약물 전달 시스템
|
|
US20210330599A1
(en)
|
2016-08-01 |
2021-10-28 |
University Of Rochester |
Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
|
|
WO2018039508A1
(en)
|
2016-08-25 |
2018-03-01 |
Merial, Inc. |
Method for reducing unwanted effects in parasiticidal treatments
|
|
US10449230B2
(en)
|
2016-10-06 |
2019-10-22 |
The Regents Of The University Of California |
Polymyxin derived cell penetrating scaffolds
|
|
CN110381738B
(zh)
|
2016-10-14 |
2021-07-16 |
勃林格殷格翰动物保健美国公司 |
农药的和杀寄生物的乙烯基异噁唑啉化合物
|
|
JP7414525B2
(ja)
|
2016-11-03 |
2024-01-16 |
ウー,ローレンス,アイ. |
クロファラビンのプロドラッグ
|
|
JP7113009B2
(ja)
|
2016-11-07 |
2022-08-04 |
アービュタス バイオファーマ コーポレイション |
置換ピリジノン含有三環式化合物およびそれを使用する方法
|
|
US11046680B1
(en)
|
2016-11-16 |
2021-06-29 |
Amgen Inc. |
Heteroaryl-substituted triazoles as APJ receptor agonists
|
|
BR112019009977A2
(pt)
|
2016-11-16 |
2019-08-27 |
Boehringer Ingelheim Animal Health Usa Inc |
compostos depsipeptídicos anti-helmínticos
|
|
US10736883B2
(en)
|
2016-11-16 |
2020-08-11 |
Amgen Inc. |
Triazole furan compounds as agonists of the APJ receptor
|
|
US11020395B2
(en)
|
2016-11-16 |
2021-06-01 |
Amgen Inc. |
Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
|
|
US11191762B2
(en)
|
2016-11-16 |
2021-12-07 |
Amgen Inc. |
Alkyl substituted triazole compounds as agonists of the APJ Receptor
|
|
US10689367B2
(en)
|
2016-11-16 |
2020-06-23 |
Amgen Inc. |
Triazole pyridyl compounds as agonists of the APJ receptor
|
|
WO2018093579A1
(en)
|
2016-11-16 |
2018-05-24 |
Amgen Inc. |
Triazole phenyl compounds as agonists of the apj receptor
|
|
EP4134080B1
(en)
|
2016-11-23 |
2024-11-13 |
ChemoCentryx, Inc. |
Ccr2 inhibitors for use in treating renal diseases
|
|
WO2018106928A1
(en)
|
2016-12-08 |
2018-06-14 |
Contravir Pharmaceuticals, Inc. |
Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
|
|
EP4095135A1
(en)
|
2016-12-14 |
2022-11-30 |
Intervet International B.V. |
Aminopyrazoles as selective janus kinase inhibitors
|
|
EP3601216B1
(en)
|
2017-03-21 |
2023-10-25 |
Arbutus Biopharma Corporation |
Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same for the treatment of hepatitis b virus infection
|
|
CA3058806A1
(en)
|
2017-04-03 |
2018-10-11 |
Coherus Biosciences Inc. |
Ppar.gamma. agonist for treatment of progressive supranuclear palsy
|
|
AR111464A1
(es)
|
2017-04-14 |
2019-07-17 |
Contravir Pharmaceuticals Inc |
Terapia combinada para el tratamiento de infecciones virales
|
|
DE202017002464U1
(de)
|
2017-05-09 |
2017-06-12 |
St. Lotus Biotech Corp. |
Pflanzliche Zusammensetzung zur Vorbeugung oder Linderung von ischämischem Schlaganfall
|
|
US11484543B2
(en)
|
2017-05-18 |
2022-11-01 |
The Rockefeller University |
Compositions and methods for diagnosing and treating diseases and disorders associated with mutant KCNJ5
|
|
KR102704242B1
(ko)
|
2017-06-20 |
2024-09-09 |
임브리아 파마슈티칼스, 인크. |
심장 대사의 효율을 증가시키기 위한 조성물 및 방법
|
|
JP7198269B2
(ja)
|
2017-08-08 |
2022-12-28 |
ケモセントリックス,インコーポレイティド |
大員環免疫調節剤
|
|
ES2944616T3
(es)
|
2017-08-14 |
2023-06-22 |
Boehringer Ingelheim Animal Health Usa Inc |
Compuestos de pirazol-isoxazolina plaguicidas y parasiticidas
|
|
WO2019038764A1
(en)
|
2017-08-23 |
2019-02-28 |
Gavish-Galilee Bio Applications Ltd. |
COMPOSITIONS AND METHODS FOR TREATING AEROSCLASTER CARDIOVASCULAR DISEASE
|
|
JP7453139B2
(ja)
|
2017-09-25 |
2024-03-19 |
ケモセントリックス,インコーポレイティド |
ケモカイン受容体2(ccr2)アンタゴニスト及びpd-1/pd-l1阻害剤を使用した併用療法
|
|
MX386699B
(es)
|
2017-10-11 |
2025-03-19 |
Chemocentryx Inc |
Tratamiento de glomerulosclerosis segmentaria focal con antagonistas ccr2
|
|
WO2019089534A1
(en)
|
2017-10-31 |
2019-05-09 |
Chemocentryx, Inc. |
C5aR INHIBITOR REDUCTION OF URINARY sCD163
|
|
EP3704122B1
(en)
|
2017-11-03 |
2021-09-01 |
Amgen Inc. |
Fused triazole agonists of the apj receptor
|
|
WO2019104316A1
(en)
|
2017-11-27 |
2019-05-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compounds, compositions, and methods for treating and/or preventing periodontal disease
|
|
SG11202005799XA
(en)
|
2017-12-22 |
2020-07-29 |
Chemocentryx Inc |
DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
|
|
MA51331A
(fr)
|
2017-12-22 |
2020-10-28 |
Chemocentryx Inc |
COMPOSÉS CYCLIQUES CONDENSÉS 6,5 À SUBSTITUTION DIARYLE, UTILISÉS EN TANT QU'INHIBITEURS DU C5aR
|
|
CN111867579B
(zh)
|
2018-01-08 |
2023-11-24 |
凯莫森特里克斯股份有限公司 |
Ccr6或cxcr2拮抗剂治疗泛发性脓疱型银屑病的方法
|
|
WO2019141957A1
(en)
|
2018-01-19 |
2019-07-25 |
Cado Biotechnology Ivs |
N-pyrimidinyl hydroxy pyrazole derivatives and uses thereof
|
|
JP2021513512A
(ja)
|
2018-02-05 |
2021-05-27 |
シェンチェン イオノヴァ ライフ サイエンス カンパニー リミテッドShenzhen Ionova Life Science Co., Ltd. |
癌または炎症性疾患の治療のためのヘテロ二環式カルボキシ酸
|
|
US11583545B2
(en)
|
2018-02-08 |
2023-02-21 |
Boehringer Ingelheim Animal Health USA Inc. |
Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof
|
|
CA3091088A1
(en)
|
2018-02-13 |
2019-08-22 |
Beetlebung Pharma Ltd. |
Cannabinoid derivatives and conjugates and uses thereof
|
|
WO2019165043A2
(en)
|
2018-02-22 |
2019-08-29 |
Chemocentryx, Inc. |
Indane-amines as pd-l1 antagonists
|
|
US10982210B2
(en)
|
2018-03-02 |
2021-04-20 |
Sixfold Bioscience Ltd. |
Compositions for delivery of cargo to cells
|
|
WO2019191032A1
(en)
|
2018-03-26 |
2019-10-03 |
Clear Creek Bio, Inc. |
Compositions and methods for inhibiting dihydroorotate dehydrogenase
|
|
WO2019190823A1
(en)
|
2018-03-28 |
2019-10-03 |
Vtv Therapeutics Llc |
Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
|
|
WO2019190822A1
(en)
|
2018-03-28 |
2019-10-03 |
Vtv Therapeutics Llc |
Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
|
|
BR112020019822A2
(pt)
|
2018-04-02 |
2021-03-16 |
Chemocentryx, Inc. |
Profármacos de antagonistas bicíclicos fundidos de c5ar
|
|
EP3552605A1
(en)
|
2018-04-11 |
2019-10-16 |
Univerzita Palackého V Olomouchi |
Mcoppb for use as medicament
|
|
US11807624B2
(en)
|
2018-05-01 |
2023-11-07 |
Amgen Inc. |
Substituted pyrimidinones as agonists of the APJ receptor
|
|
MX2020012805A
(es)
|
2018-05-29 |
2021-02-15 |
Cersci Therapeutics Inc |
Compuestos para el tratamiento del dolor, composiciones que comprenden los mismos, y metodos para utilizar los mismos.
|
|
US20190374607A1
(en)
|
2018-06-08 |
2019-12-12 |
The Medical College Of Wisconsin, Inc. |
Methods of treating vascular leakage using cxcl12 peptides
|
|
US12383545B1
(en)
|
2018-06-08 |
2025-08-12 |
Allergan Pharmaceuticals International Limited |
Treatment of migraine
|
|
EP3820870A1
(en)
|
2018-07-09 |
2021-05-19 |
Boehringer Ingelheim Animal Health USA Inc. |
Anthelminthic heterocyclic compounds
|
|
TWI869058B
(zh)
|
2018-07-27 |
2025-01-01 |
加拿大商愛彼特生物製藥公司 |
經取代四氫環戊[c]吡咯、經取代二氫吡咯,其類似物及使用其之方法
|
|
US10966943B2
(en)
|
2018-09-06 |
2021-04-06 |
Innopharmascreen Inc. |
Methods and compositions for treatment of asthma or parkinson's disease
|
|
JP7464591B2
(ja)
|
2018-10-10 |
2024-04-09 |
ブイティーブイ・セラピューティクス・エルエルシー |
[3-(4-{2-ブチル-1-[4-(4-クロロ-フェノキシ)-フェニル]-1h-イミダゾール-4-イル}-フェノキシ)-プロピル]-ジエチル-アミンの代謝産物
|
|
US12318382B2
(en)
|
2018-10-17 |
2025-06-03 |
Imbria Pharmaceuticals, Inc. |
Methods of treating rheumatic diseases using trimetazidine-based compounds
|
|
US12030872B2
(en)
|
2018-10-31 |
2024-07-09 |
Merck Sharp & Dohme Llc |
N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
|
|
WO2020092845A1
(en)
|
2018-11-01 |
2020-05-07 |
Rigel Pharmaceuticals, Inc. |
Method and composition embodiments for treating acute myeloid leukemia
|
|
US11773066B2
(en)
|
2018-11-20 |
2023-10-03 |
Boehringer Ingelheim Animal Health USA Inc. |
Indazolylcyanoethylamino compound, compositions of same, method of making, and methods of using thereof
|
|
TWI827760B
(zh)
|
2018-12-12 |
2024-01-01 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
|
WO2020159588A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
|
|
US20200246316A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
|
|
CN119285648A
(zh)
|
2019-03-19 |
2025-01-10 |
勃林格殷格翰动物保健有限公司 |
驱虫的氮杂-苯并噻吩和氮杂-苯并呋喃化合物
|
|
WO2020227603A1
(en)
|
2019-05-09 |
2020-11-12 |
The Feinstein Institutes For Medical Research |
Hmgb1 antagonist
|
|
US20200377518A1
(en)
|
2019-05-29 |
2020-12-03 |
Rigel Pharmaceuticals, Inc. |
Method of preventing and treating thrombosis
|
|
US12319671B2
(en)
|
2019-06-06 |
2025-06-03 |
Merck Sharp & Dohme Llc |
1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
|
|
JP7693644B2
(ja)
|
2019-07-08 |
2025-06-17 |
リゾルート,インコーポレイティド |
血漿カリクレイン阻害薬の調製プロセス
|
|
KR102890201B1
(ko)
|
2019-07-10 |
2025-11-24 |
케모센트릭스, 인크. |
Pd-l1 억제제로서의 인단
|
|
JP7682155B2
(ja)
|
2019-08-08 |
2025-05-23 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
サイトカイン放出症候群を治療するための化合物及び方法
|
|
MX2022001890A
(es)
|
2019-08-14 |
2022-04-26 |
Rigel Pharmaceuticals Inc |
Metodo para bloquear o mejorar el sindrome de liberacion de citocinas.
|
|
CR20220216A
(es)
|
2019-10-16 |
2023-01-09 |
Chemocentryx Inc |
Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
|
|
EP4045036A4
(en)
|
2019-10-16 |
2023-11-15 |
ChemoCentryx, Inc. |
Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
|
|
CA3154247A1
(en)
|
2019-10-25 |
2021-04-29 |
Mitchell H. KEYLOR |
N-(heteroaryl) quinazolin-2-amine derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
|
|
CN118908882A
(zh)
|
2019-11-08 |
2024-11-08 |
凯莫森特里克斯股份有限公司 |
补体成分c5a受体的盐形式
|
|
US10792360B1
(en)
|
2019-11-21 |
2020-10-06 |
Chemocentryx, Inc. |
Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
|
|
WO2021123394A1
(en)
|
2019-12-20 |
2021-06-24 |
University Of Copenhagen |
G protein-coupled receptor modulators and a pharmaceutical composition
|
|
WO2021189018A1
(en)
|
2020-03-20 |
2021-09-23 |
Clear Creek Bio, Inc. |
Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
|
|
US20230149400A1
(en)
|
2020-03-27 |
2023-05-18 |
Aclaris Therapeutics, Inc. |
Methods and compositionsfor treating viral infections
|
|
CN115484944A
(zh)
|
2020-03-31 |
2022-12-16 |
坎莫森特里克斯公司 |
使用ccr9抑制剂和抗il-23阻断抗体治疗炎症性肠病的组合物和方法
|
|
JP2023522985A
(ja)
|
2020-04-23 |
2023-06-01 |
エーゼットセラピーズ, インコーポレイテッド |
Hlaクラスi mhcの細胞切除
|
|
EP3901160A1
(en)
|
2020-04-25 |
2021-10-27 |
Nuvamid SA |
Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
|
|
US20230150984A1
(en)
|
2020-04-24 |
2023-05-18 |
Nuvamid Sa |
Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
|
|
CN115997016A
(zh)
|
2020-04-27 |
2023-04-21 |
西克斯福德生物科学有限公司 |
包含具有模块化官能团的核酸纳米颗粒的组合物
|
|
CA3176169A1
(en)
|
2020-04-30 |
2021-11-04 |
Annette M. TOBIA |
Compositions and methods for treating cytokine storms
|
|
IL298501A
(en)
|
2020-05-28 |
2023-01-01 |
Aztherapies Inc |
Car-treg-based therapies targeting myelin oligodendrocyte glycoprotein (mog) for treating neurodegenerative diseases
|
|
CR20220665A
(es)
|
2020-05-29 |
2023-07-19 |
Boehringer Ingelheim Pharma |
Compuestos heterocíclicos como anthelmínticos
|
|
US11780811B2
(en)
|
2020-06-30 |
2023-10-10 |
Imbria Pharmaceuticals, Inc. |
Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
|
US11530184B2
(en)
|
2020-06-30 |
2022-12-20 |
Imbria Pharmaceuticals, Inc. |
Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
|
AU2021304808A1
(en)
|
2020-07-07 |
2023-02-09 |
Atxa Therapeutics Limited |
Thromboxane receptor antagonist formulations
|
|
EP4182326A1
(en)
|
2020-07-17 |
2023-05-24 |
Université de Bretagne Occidentale |
New glycolipids and use thereof as sk3 ion channel modulators
|
|
JP2023535744A
(ja)
|
2020-07-29 |
2023-08-21 |
アラーガン ファーマシューティカルズ インターナショナル リミテッド |
片頭痛の治療
|
|
WO2022029275A1
(en)
|
2020-08-06 |
2022-02-10 |
Nuvamid Sa |
Combination of nicotinamide mononucleotide derivatives and other therapeutic agents for use in the treatment of coronavirus infections and covid-19
|
|
AU2021322736A1
(en)
|
2020-08-07 |
2023-03-02 |
Nuvamid Sa |
Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of an antineoplastic-induced toxicity
|
|
BR112023002608A2
(pt)
|
2020-08-12 |
2023-05-09 |
Txp Pharma Ag |
Análogo de peptídeo de exendina-4, e, método para tratamento de diabetes mellitus tipo 2, obesidade e/ou intensificação da saciedade
|
|
KR20230090336A
(ko)
|
2020-10-13 |
2023-06-21 |
베타바이브 리미티드 |
당뇨병 및 관련된 대사성 질환을 치료하기 위한 방법 및 화합물
|
|
EP4236950A4
(en)
|
2020-10-29 |
2024-10-23 |
Merck Sharp & Dohme LLC |
N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
|
|
GB202017251D0
(en)
|
2020-10-30 |
2020-12-16 |
Queens Univ Of Belfast |
Neurodegenerative treatment
|
|
GB202017255D0
(en)
|
2020-10-30 |
2020-12-16 |
Queens Univ Of Belfast |
Immunomodulatory agent
|
|
US11844754B2
(en)
|
2020-11-17 |
2023-12-19 |
Neuroderm, Ltd. |
Methods for treatment of Parkinson's disease
|
|
US11331293B1
(en)
|
2020-11-17 |
2022-05-17 |
Neuroderm, Ltd. |
Method for treatment of Parkinson's disease
|
|
US11213502B1
(en)
|
2020-11-17 |
2022-01-04 |
Neuroderm, Ltd. |
Method for treatment of parkinson's disease
|
|
US11969422B2
(en)
|
2020-12-10 |
2024-04-30 |
Imbria Pharmaceuticals, Inc. |
Methods of treating heart failure with reduced ejection fraction using modified forms of trimetazidine
|
|
US12076318B2
(en)
|
2020-12-10 |
2024-09-03 |
Imbria Pharmaceuticals, Inc. |
Methods of treating heart failure with hibernating myocardium using modified forms of trimetazidine
|
|
US11793807B2
(en)
|
2020-12-10 |
2023-10-24 |
Imbria Pharmaceuticals, Inc. |
Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine
|
|
US11730733B2
(en)
|
2020-12-10 |
2023-08-22 |
Imbria Pharmaceuticals, Inc. |
Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine
|
|
US12403153B2
(en)
|
2020-12-18 |
2025-09-02 |
Nuvamid Sa |
Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of a red blood cell disorder
|
|
US20240299318A1
(en)
|
2021-02-08 |
2024-09-12 |
Bausch Health Ireland Limited |
Amiselimod for preventing, treating or ameliorating ulcerative colitis
|
|
WO2022184685A1
(en)
|
2021-03-01 |
2022-09-09 |
Nuvamid Sa |
Nicotinamide mononucleotide derivatives and use thereof for the treatment and/or prevention of long covid-19
|
|
EP4070799A1
(en)
|
2021-04-08 |
2022-10-12 |
Nuvamid SA |
Compositions for the improvement of sport performance
|
|
EP4079310A1
(en)
|
2021-04-20 |
2022-10-26 |
Nuvamid SA |
Nmn and derivatives for its use in the treatment of alpha-synucleinopathies
|
|
EP4079311B1
(en)
|
2021-04-20 |
2025-10-01 |
Nuvamid SA |
Nmn and derivatives for use in the treatment of depression and/or anxiety in patients having a form of parkinsonism
|
|
US11883396B2
(en)
|
2021-05-03 |
2024-01-30 |
Imbria Pharmaceuticals, Inc. |
Methods of treating kidney conditions using modified forms of trimetazidine
|
|
WO2022254425A1
(en)
|
2021-05-31 |
2022-12-08 |
Cannabotech Ltd. |
Compositions comprising a cannabinoid and uses thereof
|
|
US20240382511A1
(en)
|
2021-06-17 |
2024-11-21 |
Nuvamid Sa |
Nicotinamide mononucleotide derivatives and use thereof for the treatment of heart failure with preserved ejection fraction
|
|
EP4355743A1
(en)
|
2021-06-18 |
2024-04-24 |
University of Copenhagen |
Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists
|
|
WO2023012182A1
(en)
|
2021-08-02 |
2023-02-09 |
Nuvamid Sa |
Nicotinamide mononucleotide derivatives for use in the treatment of sapho syndrome
|
|
WO2023023532A2
(en)
|
2021-08-18 |
2023-02-23 |
Chemocentryx, Inc. |
Aryl sulfonyl (hydroxy) piperidines as ccr6 inhibitors
|
|
US12350259B2
(en)
|
2021-09-27 |
2025-07-08 |
Allergan Pharmaceuticals International Limited |
Methods of treating migraine
|
|
JP2024537329A
(ja)
|
2021-10-12 |
2024-10-10 |
ベータヴァイヴ・リミテッド |
糖尿病及び関連する代謝性疾患を処置するためのペプチド及び断片
|
|
AU2023336062A1
(en)
|
2022-09-02 |
2025-03-13 |
Merck Sharp & Dohme Llc |
Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
|
|
IL319372A
(en)
|
2022-09-06 |
2025-05-01 |
Hadasit Med Res Service |
Combinations involving psychedelic drugs for the treatment of chronic schizophrenia and other neuropsychiatric and neurological disorders
|
|
PE20251547A1
(es)
|
2022-10-25 |
2025-06-05 |
Merck Sharp And Dohme Llc |
Enlazadores-cargas utiles de adc derivados de exatecan, composiciones farmaceuticas, y usos de los mismos
|
|
EP4633681A1
(en)
|
2022-12-14 |
2025-10-22 |
Merck Sharp & Dohme LLC |
Auristatin linker-payloads, pharmaceutical compositions, and uses thereof
|
|
US12091400B2
(en)
|
2023-01-20 |
2024-09-17 |
Epics Therapeutics |
Piperidine derivatives as METTL3 inhibitors
|
|
WO2024194175A1
(en)
|
2023-03-17 |
2024-09-26 |
Atmosr |
Adenine derivatives as hsp90 inhibitors
|
|
US12161612B2
(en)
|
2023-04-14 |
2024-12-10 |
Neuroderm, Ltd. |
Methods and compositions for reducing symptoms of Parkinson's disease
|
|
WO2025011733A1
(en)
|
2023-07-07 |
2025-01-16 |
Nuvamid Sa |
Nicotinamide mononucleotide and derivatives thereof and use thereof in the treatment and prevention of polycythemia
|
|
US20250057848A1
(en)
|
2023-08-14 |
2025-02-20 |
Neurim Pharmaceuticals (1991) Ltd. |
Gal475 compositions and methods of use thereof
|
|
WO2025064408A1
(en)
|
2023-09-18 |
2025-03-27 |
The Broad Institute, Inc. |
Compositions and methods for treating cardiovascular disease
|
|
WO2025099725A1
(en)
|
2023-11-09 |
2025-05-15 |
Hadasit Medical Research Services And Development Ltd. |
Conjugates and uses thereof
|
|
GB2636364A
(en)
|
2023-12-07 |
2025-06-18 |
Aramune Tech Limited |
Arabinogalactan
|
|
WO2025134072A1
(en)
|
2023-12-21 |
2025-06-26 |
Bausch Health Ireland Limited |
Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod
|
|
WO2025176994A1
(en)
|
2024-02-20 |
2025-08-28 |
Analytical Services For Art & Archaeology (Scotland) Ltd |
Composition and method of use
|
|
WO2025219976A1
(en)
|
2024-04-19 |
2025-10-23 |
Betavive Ltd. |
Peptides and fragments for treating diabetes and associated metabolic diseases
|
|
GB202405650D0
(en)
|
2024-04-22 |
2024-06-05 |
Royal College Surgeons Ireland |
Hdac6 protacs
|